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ARTICLE
Partial inhibition of mitochondrial complex I
ameliorates Alzheimer’s disease pathology
and cognition in APP/PS1 female mice
Andrea Stojakovic1,15, Sergey Trushin1,15, Anthony Sheu2,15, Layla Khalili1, Su-Youne Chang3,4, Xing Li 5,
Trace Christensen6, Jeffrey L. Salisbury6,7, Rachel E. Geroux1, Benjamin Gateno1, Padraig J. Flannery1,
Mrunal Dehankar5, Cory C. Funk 8, Jordan Wilkins1, Anna Stepanova9, Tara O’Hagan9, Alexander Galkin 9,
Jarred Nesbitt1, Xiujuan Zhu1, Utkarsh Tripathi1, Slobodan Macura 7, Tamar Tchkonia 10,
Tamar Pirtskhalava10, James L. Kirkland 10, Rachel A. Kudgus11, Renee A. Schoon11, Joel M. Reid11,
Yu Yamazaki12, Takahisa Kanekiyo 12, Song Zhang 13, Emirhan Nemutlu 14, Petras Dzeja13,
Adam Jaspersen6, Ye In Christopher Kwon2, Michael K. Lee2,16 & Eugenia Trushina 1,11,16✉
Alzheimer’s Disease (AD) is a devastating neurodegenerative disorder without a cure. Here
we show that mitochondrial respiratory chain complex I is an important small molecule
druggable target in AD. Partial inhibition of complex I triggers the AMP-activated protein
kinase-dependent signaling network leading to neuroprotection in symptomatic APP/PS1
female mice, a translational model of AD. Treatment of symptomatic APP/PS1 mice with
complex I inhibitor improved energy homeostasis, synaptic activity, long-term potentiation,
dendritic spine maturation, cognitive function and proteostasis, and reduced oxidative stress
and inflammation in brain and periphery, ultimately blocking the ongoing neurodegeneration.
Therapeutic efficacy in vivo was monitored using translational biomarkers FDG-PET, 31P
NMR, and metabolomics. Cross-validation of the mouse and the human transcriptomic data
from the NIH Accelerating Medicines Partnership–AD database demonstrated that pathways
improved by the treatment in APP/PS1 mice, including the immune system response and
neurotransmission, represent mechanisms essential for therapeutic efficacy in AD patients.
https://doi.org/10.1038/s42003-020-01584-y OPEN
A list of author affiliations appears at the end of the paper.









A lzheimer’s disease (AD) is a multifactorial disorderwithout a cure. It is characterized by progressive accu-mulation of aggregated amyloid β (Aβ) peptides and
hyperphosphorylated Tau protein, memory decline, and neuro-
degeneration. The consistent failure of clinical trials focused on
reducing Aβ levels and aggregation suggests that such therapies
may not work in AD patients regardless of disease stage,
underscoring the need to discover novel targets and therapies for
AD1–3. Recent studies demonstrated that altered energy home-
ostasis associated with reduced cerebral glucose uptake and uti-
lization, altered mitochondrial function and microglia
and astrocyte activation might underlie neuronal dysfunction in
AD4–8. Intriguingly, accumulating evidence suggests that non-
pharmacological approaches, such as diet and exercise, reduce
major AD hallmarks by engaging an adaptive stress response that
leads to improved metabolic state, reduced oxidative stress and
inflammation, and improved proteostasis9. While mechanisms of
the stress response are complex, AMP-activated protein kinase
(AMPK)-mediated signaling has been directly linked to the reg-
ulation of cell metabolism, mitochondrial dynamics and function,
inflammation, oxidative stress, protein turnover, Tau phosphor-
ylation, and amyloidogenesis10. Combined analysis performed
using multiple types of genome-wide data identified a pre-
dominant role for metabolism-associated biological processes in
the course of AD, including autophagy and insulin and fatty acid
metabolism, with a focus on AMPK as a key modulator and
therapeutic target11. However, the development of direct phar-
macological AMPK activators to elicit beneficial effects has pre-
sented multiple challenges12. We recently demonstrated that mild
inhibition of mitochondrial complex I (MCI) with the small
molecule tricyclic pyrone compound CP2 blocked cognitive
decline in transgenic mouse models of AD when treatment was
started in utero through life or at a pre-symptomatic stage of the
disease13,14. Moreover, in neurons, CP2 restored mitochondrial
dynamics and function and cellular energetics. However, it was
unclear whether MCI inhibition would elicit similar benefits if
administered at the advanced stage of the disease, after the
development of prominent Aβ accumulation, brain hypometa-
bolism, cognitive dysfunction, and progressive neurodegenera-
tion. As a proof of concept, we demonstrate that partial
inhibition of MCI triggers stress-induced AMPK-dependent sig-
naling cascade leading to neuroprotection and a reversal of
behavior changes in symptomatic APP/PS1 female mice, a
translational model of AD. Beneficial effect of treatment could be
monitored using translational biomarkers currently utilized in
clinical trials.
Results
CP2 activates AMPK-dependent neuroprotective pathways and
restores cognitive and motor function in symptomatic APP/
PS1 mice. The tricyclic pyrone, CP2, specifically inhibits the
activity of MCI in human and mouse brain mitochondria13
(Fig. 1a–c). CP2 penetrates the blood-brain barrier (BBB) and
accumulates in mitochondria, mildly decreasing MCI activity,
which leads to an increase in AMP/ATP ratio and AMPK acti-
vation13. CP2 was effective in blocking cognitive dysfunction
when treatment was administered to pre-symptomatic mice
carrying familial mutations in the APP(K670N/M671L) and PS1
(M146L) genes (referred to as APP/PS1 mice)13,14. To determine
whether CP2 could engage AMPK-dependent neuroprotective
mechanisms (Fig. 1d) in symptomatic mice, we administered a
single oral dose to 9-10-month-old APP/PS1 mice and examined
the expression of key proteins in each pathway after 4, 24, 48,
and 72 h (Fig. 1e–l, Supplementary Figs. 1a, 2). An independent
cohort of CP2-treated APP/PS1 mice was assayed using in vivo
18F-fluorodeoxyglucose positron emission tomography (FDG-
PET) and compared to non-transgenic (NTG) untreated litter-
mates (Fig. 1h, Supplementary Fig. 1b). Consistent with previous
observations, CP2 robustly activated AMPK after 24 h, when
increased phosphorylation of acetyl-CoA carboxylase 1 (ACC1),
a biomarker of AMPK target engagement associated with
increased fatty acid oxidation15, was evident 4 h after CP2
administration (Fig. 1f, Supplementary Figs. 1a, 2). Remarkably,
a substantial increase in the glucose transporters, Glut 3 and 4,
was observed as early as 4 h after CP2 treatment that persisted
for 24 and 48 h, consistent with the established role of AMPK in
the maintenance of glucose uptake in the brain16–18 (Fig. 1g,
Supplementary Figs. 1a, 2). Improved glucose uptake in APP/PS1
mice was independently established using in vivo FDG-PET
(Fig. 1h, Supplementary Fig. 1b). A decreased ratio of phos-
phorylated vs. total pyruvate dehydrogenase (PDH) at 24 and 48
h confirmed that augmented glucose uptake was associated with
improved glucose utilization (Fig. 1g, Supplementary Figs. 1a, 2),
since increased PDH activity leads to acetyl-CoA production
from pyruvate in the glucose catabolism pathway, promoting
energy production in mitochondria19. Furthermore, increased
expression of the transcriptional coactivator, peroxisome
proliferator-activated receptor-γ coactivator-1α (PGC-1α),
mitochondrial transcription factor A (TFAM), and
mitochondria-specific neuroprotective Sirtuin 3 (Sirt3), supports
the view that there was improved mitochondrial biogenesis and
function (Fig. 1i, Supplementary Figs. 1a, 2)20,21. We further
confirmed that CP2 induces an anti-inflammatory mechanisms
evident by increased levels of IκBα and decreased phosphoryla-
tion of p65, which together block NF-κB transcription factor
activation (Fig. 1j, Supplementary Figs. 1a, 2)22. In addition, CP2
activates nuclear factor E2-related factor 2 (Nrf 2)-dependent
expression of antioxidants including heme oxygenase (HO1),
superoxide dismutase (SOD1), and catalases (Fig. 1k, Supple-
mentary Figs. 1a, 2)23. Finally, CP2 treatment increased autop-
hagy based on changes in the autophagy activating kinase ULK1,
Beclin1 and LC3B proteins essential for autophagosome forma-
tion (Fig. 1l, Supplementary Fig. 1a, 2)24. These data demonstrate
that oral CP2 administration activates the neuroprotective
AMPK signaling network in symptomatic APP/PS1 mice at
therapeutic doses.
To determine the therapeutic efficacy of chronic administra-
tion, we treated symptomatic APP/PS1 female mice with CP2 (25
mg/kg/day in drinking water ad lib) from 9 until 23 months of
age (Fig. 2a). NTG female age-matched littermates were controls.
All treated mice tolerated CP2 well; they did not manifest side
effects and gained weight throughout the duration of the study
with an increase in lean and fat mass (Fig. 2b, Supplementary
Fig. 3a–l). Data generated using indirect calorimetry (CLAMS)
demonstrated that CP2-treated and vehicle-treated NTG mice
had similar food intake (Supplementary Fig. 3b). Metabolic rate at
rest was decreased by CP2 treatment only in NTG mice
(Supplementary Fig. 3c). Since general daily activity of vehicle-
treated and CP2-treated NTG mice was not different (Fig. 2f), the
significant weight gain observed in CP2-treated NTG mice could
be associated with reduced metabolic rate and lower energy
expenditure. In comparison to NTG mice, vehicle-treated APP/
PS1 mice displayed lower body weight, higher food intake,
increased metabolic rate and motor activity (Supplementary
Fig. 3a–c, Fig. 2f). This is consistent with previous findings
showing that AD mice have elevated caloric intake, hypermeta-
bolism and lower body weight25. The weight gain in CP2-treated
APP/PS1 could be explained by increased food intake and
attenuated hyperactivity, while metabolic rate remained similar
between CP2-treated and vehicle-treated groups (Fig. 2b,f,
Supplementary Fig. 3a–c). Since CP2 treatment did not increase
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food intake in NTG mice, it is feasible that increased food intake
in CP2-treated APP/PS1 mice could be related to more frequent
feeding due to ameliorated hyperactivity.
Results of behavioral tests confirmed that CP2-treated APP/
PS1 mice had improved spatial memory and learning (Morris
Water Maze, Fig. 2c, d), restoration of attention and non-spatial
declarative memory (Novel Object Recognition, Fig. 2e), reduced
hyperactivity in the open field test (Fig. 2f), and increased
strength and motor coordination (rotarod, hanging bar, Fig. 2g,
h). CP2 penetrates the BBB13,14 and has oral bioavailability of
65% (Supplementary Fig. 4). CP2 concentrations measured in the
brain at the end of the study averaged at ~62 nM (Supplementary
Table 1), consistent with earlier bioavailability studies13,14. To
establish CP2 selectivity and specificity, we conducted in vitro
pharmacological profiling against 44 human targets, including G-
protein-coupled receptors, ion channels, enzymes, neurotrans-
mitter transporters, and 250 kinases (Supplementary Tables 2–3,
Supplementary Data 1). At 1 and 10 μM, concentrations higher
than those found in the brain tissue of chronically treated mice
(Supplementary Table 1), CP2 had minimal off-target activities
demonstrating its selectivity at therapeutic doses. These observa-
tions reveal that chronic treatment with MCI inhibitor CP2
improves cognitive and motor function in APP/PS1 mice to that
of NTG mice after the onset of significant accumulation of Aβ
plaques26, and development of behavioral27 and mitochondrial
dysfunction28.
CP2 treatment improves glucose uptake and utilization and
metabolic flexibility in symptomatic APP/PS1 mice. We next
determined the effect of chronic CP2 treatment on brain energy
homeostasis. Similarly to AD patients, glucose utilization in the
brain of APP/PS1 mice measured using FDG-PET imaging was
significantly reduced (Figs. 1h, 3a, b). Consistent with results of
the acute administration (Fig. 1h), chronic CP2 treatment over
9 months alleviated pronounced brain glucose hypometabolism
in APP/PS1 mice (Fig. 3a, b). Data generated using CLAMS
provided further evidence that, compared to untreated counter-
parts, CP2 treatment in APP/PS1 mice increased carbohydrate
oxidation and metabolic flexibility, an essential ability to switch
between lipid and carbohydrate oxidation that is affected in
metabolic diseases and aging (Fig. 3c–e). Consistent with the
improved regulation of glucose metabolism, CP2-treated APP/
PS1 and NTG mice had decreased fasting plasma insulin levels
and better insulin sensitivity and glucose tolerance (Fig. 3f–h).
Western blot analysis in brain tissue revealed increased expres-
sion of Glut 3 and 4 and a decreased ratio of pPDH/PDH
a)
APP/PS1 mice
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Fig. 1 Acute CP2 treatment activates multiple AMPK-dependent neuroprotective mechanisms in symptomatic APP/PS1 mice improving energy
homeostasis in the brain. a CP2 structure. b CP2 (light gray bars, 50mM) does not affect the activity of succinate oxidase (complexes II-III-IV), succinate:
cytochrome c reductase (complexes II-III), and ferrocytochrome c oxidase (complex IV only), but significantly inhibits MCI affecting NADH oxidase
(complexes I-III-IV) and NADH:ubiquinone (complex I only) in mouse brain mitochondria. Vehicle-dark gray bars. c CP2 inhibits MCI in mitochondria
isolated from the mouse and postmortem human cortical tissue. d Neuroprotective pathways activated by CP2 in the brain converge on AMPK activation.
e Timeline of acute CP2 administration via gavage (25mg/kg) to APP/PS1 mice 9–10-month-old. Brain tissues from 1 mouse per each time point were
examined using western blot analysis. Independent cohort of mice was subjected to the in vivo FDG-PET (n= 3 mice per group). f–l Western blot analysis
of brain tissue from acutely gavaged APP/PS1 mice from e confirms that CP2 activates multiple AMPK-dependent neuroprotective mechanisms in
symptomatic APP/PS1 mice. h Untreated symptomatic APP/PS1 mice 9–10-month-old have reduced glucose uptake in the brain determined using in vivo
FDG-PET compared to NTG littermates (time 0 h). Acute CP2 oral administration improves glucose uptake brining glucose levels in APP/PS1 mice to the
same level as in untreated age-matched and sex-matched NTG mice (time 24 and 72 h); n= 3 mice per group.
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indicative of improved glucose uptake and utilization together
with enhanced signaling through the IGF pathway (Fig. 3i, Sup-
plementary Figs. 5, 6).
Since CP2 inhibits MCI, we examined if chronic treatment affects
ATP levels in the brain using 31P nuclear magnetic resonance (31P
NMR) spectroscopy (Fig. 3j, k). This method allows non-invasive
measurement of in vivo energy metabolite concentrations including
phosphocreatine (PCr), inorganic phosphates (Pi), and the α, β, and
γ phosphate groups of ATP (Fig. 1j). Chronic CP2 treatment over
10 months did not decrease the PCr/ATP ratio in APP/PS1 or NTG
mice (Fig. 3k) consistent with improved glucose uptake/utilization.
As a second measure, we performed metabolomic profiling in brain
of vehicle-treated and CP2-treated APP/PS1 and NTG mice treated
with CP2 for 6 months (Supplementary Table 4). In agreement with
target engagement, CP2 treatment increased levels of AMP in APP/
PS1 mice but did not reduce brain levels of ATP. Treatment
resulted in increased levels of citrate and N-acetyl aspartate (NAA),
markers of improved mitochondrial and neuronal function.
Importantly, levels of 2-hydroxyglutarate, a marker of detrimental
mitochondrial stress29, were not elevated, suggesting inhibition of
MCI with CP2 does not induce adverse mitochondrial stress that
could negatively regulate neuronal survival and function. Increased
levels of gamma-aminobutyrate, a metabolite involved in the
gamma-aminobutyric acid (GABA) neurotransmitter system,
indicate an improvement in neurotransmission and potential
reversal of AD-related neurodegeneration. Increased levels of
ascorbic/dehydroascorbic acids imply an improvement in vitamin
C status and redox balance in the brain, consistent with CP2-
induced activation of neuroprotective mechanisms (Fig. 1d–l).
CP2 treatment reduces Aβ-related pathology, inflammation,
and oxidative stress and improves proteostasis in brain and
periphery. Histological examination of the hippocampus and
cortex of CP2-treated APP/PS1 mice using 4G8 antibody
revealed a significant reduction in Aβ plaques compared to
untreated littermates (Fig. 4a, b). Biochemical analysis con-
ducted using sequential extraction of brain tissue showed that
CP2 treatment reduced total Aβ levels (Fig. 4c). While soluble
Aβ was increased (Fig. 4d, e), levels of insoluble peptides were
significantly decreased (Fig. 4f). Improved proteostasis could be
promoted by autophagic degradation associated with AMPK
activation and inhibition of the activity of glycogen synthase
kinase-3 (GSK3β), whose hyperactivation in AD is directly
linked to Aβ pathology30,31. Indeed, CP2-dependent AMPK
activation increased inhibitory phosphorylation of GSK3β
and promoted the expression of proteins associated with lyso-
somal biogenesis and autophagy, including the transcription
factor EB (TFEB), lysosomal-associated membrane protein 1
(LAMP-1), and microtubule-associated protein light chain 3
(LC3B) (Fig. 4g, Supplementary Figs. 7, 8). These data further
support the contention that CP2-induced autophagy is one of
the neuroprotective pathways essential for Aβ clearance
(Fig. 1d).
Since AMPK activation is known to reduce inflammation and
promote anti-oxidant response32, we examined levels of glial
fibrillary acidic protein (GFAP) and the ionized calcium-binding
adapter molecule 1 (Iba1), well-established markers of glial
activation and inflammation, in the brain of CP2-treated and
vehicle-treated APP/PS1 mice (Fig. 4h–k). Blood from the same
c)a) b)
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Fig. 2 CP2 treatment restores cognitive function in symptomatic APP/PS1 mice. a Timeline of chronic CP2 treatment. b Weight of NTG and APP/PS1
mice treated with vehicle or CP2 through the duration of the study. c–h CP2 treatment improves a performance in the Morris Water Maze (c, d) and in the
Novel Object Recognition test (e), reduces hyperactivity of APP/PS1 mice in the open field (f), and increases motor strength and coordination on the
rotating rod (g) and hanging bar (h). NTG, n= 16 mice per group; NTG+CP2, n= 20 mice per group; APP/PS1, n= 21 mice per group; APP/PS1+ CP2,
n= 19 mice per group. Data are presented as mean ± S.E.M. Data were analyzed by two-way ANOVA with Fisher’s LSD post-hoc test. A paired Student
t-test was used for statistical analysis of NOR test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Body weight data in b were analyzed by linear
regression analysis: Linear regression indicates that slopes between NTG (R squared= 0.6821) and NTG+ CP2 (R squared= 0.9181) are different (P=
0.0234); slopes between APP/PS1 (R squared= 0.04326) and APP/PS1+ CP2 (R squared= 0.7668) are different (P < 0.0001); slopes between NTG
(R squared= 0.6821) and APP/PS1 (R squared= 0.04326) are different (P= 0.0005). In all graphs: APP/PS1, orange line; NTG, black line; NTG+ CP2,
blue line; APP/PS+ CP2, red line.
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mice was profiled for cytokines and chemokines (Fig. 4l–o,
Supplementary Fig. 9a). We found that treatment significantly
reduced inflammation in the brain and periphery, decreasing glial
activation (Fig. 4h–k) and pro-inflammatory markers (e.g., IL-12,
TNFα, G-CSF, Fig. 4l–o). We next measured lipid peroxidation in
the brain, a well-established marker of oxidative stress prominent
in the hippocampus and cortex of AD patients, which correlates
with the extent of neurodegeneration and Aβ deposition33. After
13 months of CP2 treatment, levels of malondialdehyde (MDA)
were significantly reduced in both APP/PS1 and NTG mice
(Fig. 4p).
Oxidative stress and inflammation induce cell proliferation
arrest and the cell senescence phenotype, contributing to age-
related diseases. Therefore, we examined levels of senescent cells
in inguinal (ING) and periovarian (POV) adipose tissue from
NTG and APP/PS1 mice using β-Galactosidase (β-Gal) staining34
(Supplementary Fig. 9b–d). CP2 treatment significantly reduced
abundance of senescent cells in both APP/PS1 and NTG mice. In
AD patients, increased levels of ceramides, especially Cer16,
Cer18, Cer20, and Cer24, were directly linked to oxidative stress
and Aβ pathology35. Targeted metabolomic profiling conducted
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concentrations of Cer16, Cer18, and Cer24, specifically in APP/
PS1 mice (Fig. 4q–t). These data suggest that CP2 treatment
induces multiple protective mechanisms including autophagy,
anti-inflammatory and anti-oxidant responses, which contribute
to improved proteostasis, reducing Aβ pathology, which in turn
could be monitored using a translational metabolomic approach.
CP2 treatment improves synaptic function, long term poten-
tiation (LTP), dendritic spine maturation, and mitochondrial
dynamics. Synaptic loss is the best correlate of cognitive dys-
function in AD36. To determine whether augmented cognitive
performance after CP2 treatment was associated with improved
synaptic function, we analyzed excitatory postsynaptic potential
(fEPSP) in the CA1 region in acute hippocampal slices of APP/
PS1 and NTG mice measuring local field potential (Fig. 5)37. We
initially recorded basal synaptic transmission and strength of
post-synaptic responses to electrical stimulation of Schaffer col-
laterals (Fig. 5a). Activation of Schaffer collaterals revealed
reduction of fiber volley amplitudes in APP/PS1 mice compared
to NTG mice (Fig. 5b, c), which was partially restored by CP2
treatment (Fig. 5c).
Since short-term plasticity plays a crucial role in neuronal
information processing relevant to cognitive function, we next
investigated the effect of CP2 on Schaffer collaterals-CA1 short-
term plasticity utilizing a paired-pulse stimulation protocol.
Paired-pulse facilitation (PPF) measures the ability of synapses to
increase transmitter release upon the second of two closely spaced
afferent stimuli, which depends on residual calcium levels in the
presynaptic terminal38. If LTP is mediated presynaptically, an
increase in transmitter release is accompanied by a change in
short-term plasticity. We found that the PPF was not different
between groups (Fig. 5d), suggesting that CP2-dependent
improvement in LTP in APP/PS1 mice was not associated with
the pre-synaptic release of neurotransmitters. We further applied
tetanic stimulation to Schaffer collaterals-CA1 to induce and
record LTP over 60 min to determine EPSP. Significant currents
associated with strong LTP were recorded in NTG and CP2-
treated NTG and APP/PS1 mice, while vehicle-treated APP/PS1
mice did not exhibit significant LTP formation (Fig. 5e, f). These
data indicate that cognitive impairment in APP/PS1 mice could
be associated with the inability to form and maintain LTP in the
hippocampus, while CP2 treatement corrected this defect.
LTP critically depends on the morphology of dendritic spines,
which determines synaptic strength and plasticity39,40. We
examined dendritic spine morphology in the CA1 hippocampal
region of vehicle-treated and CP2-treated APP/PS1 and NTG
mice using three-dimensional electron microscopy (3D EM)
reconstruction (Fig. 6a, b)41. In NTG mice, the majority of spines
were mature (thin, stubby, mushroom, and branched), while
immature filopodia and long thin spines were prevalent in APP/
PS1 mice (Fig. 6b, c). CP2 treatment promoted maturation of
dendritic spines in APP/PS1 mice (Fig. 6b, c) and markedly
improved spine geometry (the length and width of spine necks
and heads, and compartmentalization factor) in NTG and APP/
PS1 mice, indicating greater ability to maintain LTP42 (Supple-
mentary Fig. 10). In APP/PS1 mice, CP2 treatment restored the
mushroom spine volume, length, and head width to the
dimensions observed in NTG mice (Supplementary Fig. 10a–e).
In NTG and APP/PS1 mice, CP2 significantly increased the
compartmentalization factor (Supplementary Fig. 10f), a measure
of the spine head depolarization during synaptic transmission,
which is regulated by the length of the spine neck and indicates
greater synaptic plasticity43. Increased spine maturation resulted
in more active synapses in CP2-treated APP/PS1 mice, bringing
synaptic activity to the level of NTG mice (Fig. 6d). Improved
synaptic function in CP2-treated APP/PS1 mice was associated
with increased levels of synaptophysin, the postsynaptic density
protein PSD95, and BDNF (Fig. 6e–h, Supplementary Fig. 11).
Thus, CP2-dependent cognitive protection is associated with
improved morphology of dendritic spines, LTP, and synaptic
transmission in the hippocampus.
Since synaptic activity requires energy, we examined mito-
chondrial integrity in the brain tissue of the same APP/PS1 and
NTG mice utilized in the study of dendritic spines (Fig. 6k–n).
Consistent with reports on mitochondrial fragmentation in AD,
we observed increased number of round-shaped organelles in
vehicle-treated APP/PS1 mice. CP2 treatment resulted in a higher
number of elongated organelles and increased levels of neuro-
protective Sirt3 in APP/PS1 mice (Fig. 6e, i, k–m), which could
additionally contribute to reduced inflammation and neuropro-
tection20,44,45. Interestingly, the increased mitochondrial mass
was observed only in CP2-treated NTG mice (Fig. 6n). Together
with our previous report of CP2-dependent restoration of axonal
trafficking and enhanced bioenergetics13, these data demonstrate
an improvement in mitochondrial dynamics and function in
symptomatic APP/PS1 mice, which is essential for synaptic
function and improved energy homeostasis.
CP2 treatment attenuates the ongoing neurodegeneration.
Neurons of the locus coeruleus (LC) provide norepinephrine to
the hippocampus, mediating memory and attention46. AD
patients exhibit early neurodegeneration in the LC where severity
of neuronal loss correlates with the duration of illness47. Neu-
rodegeneration in the LC has been shown to affect Aβ and Tau
Fig. 3 CP2 treatment increases glucose uptake and utilization in symptomatic APP/PS1 mice. a Glucose uptake was increased in the brain of CP2-
treated APP/PS1 mice measured using FDG-PET after 9 months of treatment. b Quantification of glucose uptake by FDG-PET imaging from a. NTG, n= 8
mice per group; NTG+ CP2, n= 4 mice per group; APP/PS1, n= 5 mice per group; APP/PS1+ CP2, n= 8 mice per group. c Changes in respiratory
exchange ratio (RER) recorded in all treatment groups over 44 h during ad lib fed and fasting states. d Glucose oxidation was increased in CP2-treated
APP/PS1 mice fed ad lib based on CLAMS data from c. Gray bars indicate fat consumption; orange bars indicate carbohydrate and protein oxidation.
e Metabolic flexibility is increased in CP2-treated APP/PS1 mice based on their ability to switch from carbohydrates to fat between feeding and fasting
states. c–e NTG, n= 16 mice per group; NTG+ CP2, n= 20 mice per group; APP/PS1, n= 15 mice per group; APP/PS1+ CP2, n= 19 mice per group.
f–h CP2 treatment reduces fasting insulin levels in plasma of APP/PS1 mice (f); increases glucose tolerance in NTG mice measured by intraperitoneal
glucose tolerance test (IPGTT) (g); and displays tendency to improve intraperitoneal insulin sensitivity test (IPIST) in NTG and APP/PS1 mice (h) after
9–10 months of treatment. n= 5 mice per group. i Western blot analysis conducted in the brain tissue of APP/PS1 mice treated with CP2 for 13 months
indicates increased IGF-1signaling, expression of Glut 3 and 4 transporters and changes in pyruvate dehydrogenase (PDH) activation associated with
glucose utilization in the TCA cycle. j Representative 31P NMR spectra with peaks corresponding to energy metabolites, including inorganic phosphate (Pi),
phosphocreatine (PCr), and three phosphate group peaks for ATP generated in living NTG and APP/PS1 mice after 9 months of vehicle or CP2 treatment.
k Phosphocreatine/ATP ratio calculated based on the 31P NMR in vivo spectra from j. NTG, n= 4 mice per group; NTG+ CP2, n= 3 mice per group;
APP/PS1, n= 6 mice per group; APP/PS1+ CP2, n= 6 mice per group. Data are presented as mean ± S.E.M. Data were analyzed by two-way ANOVA with
Fisher’s LSD post-hoc test. *P < 0.05, **P < 0.01. In all graphs: APP/PS1, orange line; NTG, black line; NTG+ CP2, blue line; APP/PS1+ CP2, red line.
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aggregation, inflammation, synaptic function, neuronal metabo-
lism, and BBB permeability48. Previously, we demonstrated that
the degeneration of LC neurons in human AD is recapitulated in
mouse models of cerebral amyloid49,50. In the current APP/PS1
mice, progressive loss of TH+ cortical afferents starts at 6 months
of age (Fig. 7a, b; Supplementary Fig. 12a, c), followed by the loss
of noradrenergic (TH+) neurons in the LC (Fig. 7c, d, Supple-
mentary Fig. 12b, d). Consistent with the progressive loss of
afferents, there was a reduction in the volume of TH+ neurons in
APP/PS1 mice starting at 12 months of age (Fig. 7e, f). Analysis of
12 month old APP/PS1 mice that received CP2 treatment for
2 months (from 10 months of age) showed that CP2 did not
impact neurodegeneration, since the cortical TH+ axon density,
the number of TH+ neurons, and neuronal volumes were similar
between vehicle-treated and CP2-treated subjects (Fig. 7b, d, f;
12-month-old group). In mice receiving CP2 for 10 months,
further progression of neurodegeneration was completely halted
by the CP2 treatment. Thus, cortical TH+ axon density, TH+
neuron number in LC, and TH+ neuronal volume in 20 month
old CP2-treated APP/PS1 mice were comparable to those in
12 month old APP/PS1 mice (Fig. 7b, d, f; 20-month-old group).
These data demonstrate that CP2 specifically protects the
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Fig. 4 CP2 treatment reduces levels of Aβ, inflammation and oxidative stress in symptomatic APP/PS1 mice. a Representative images of Aβ plaques
visualized using 4G8 antibody in S1BF cortex of NTG and APP/PS1 mice. Scale bar, 100 μm. b Levels of Aβ plaques are significantly reduced in S1BF and
hippocampus in CP2-treated APP/PS1 mice estimated using 4G8 antibody shown in a. APP/PS1 (Ctx), n= 6 mice per group; APP/PS1+ CP2 (Ctx), n= 5
mice per group; APP/PS1 (Hipp), n= 6 mice per group; APP/PS1+ CP2 (Hipp), n= 5 mice per group. c–f Differential centrifugation and ELISA revealed
decreased levels of total Aβ42 in brain homogenates from CP2-treated APP/PS1 mice (c). Levels of soluble Aβ40 and 42 obtained using TBS (d) and TBSX
(e) fractions were increased, while concentrations of the least soluble Aβ40 and 42 were decreased in brain fractions obtained using Gdn (f). c–f APP/PS1,
n= 17 mice per group; APP/PS1+CP2, n= 10 mice per group. g CP2 treatment induces AMPK activation, reduces the activity of GSK3β, and activates
autophagy in brain tissue of APP/PS1 mice. Each lane represents an individual mouse. h, j Representative images of GFAP+ (h) and Iba1+ (j) staining in
the S1BF in vehicle and CP2-treated NTG and APP/PS1 mice. Scale bar, 100 µm. i, k Quantification of GFAP (i) and Iba1 (k) staining from h and j,
respectively. NTG, n= 6 mice per group; NTG+ CP2, n= 6 mice per group; APP/PS1, n= 6 mice per group; APP/PS1+ CP2, n= 4 mice per group. l–o CP2
reduces pro-inflammatory markers in plasma of NTG and APP/PS1 mice. NTG, n= 13 mice per group; NTG+ CP2, n= 17 mice per group; APP/PS1, n= 20
mice per group; APP/PS1+ CP2, n= 16 mice per group. p Levels of lipid peroxidation measured using MDA assay were significantly reduced in brain tissue
of CP2-treated NTG and APP/PS1 mice. NTG, n= 4 mice per group; NTG+ CP2, n= 4 mice per group; APP/PS1, n= 5 mice per group; APP/PS1+ CP2, n
= 5 mice per group. q–t Concentrations of ceramides (C16, C18, C24, C24-1) were significantly reduced in blood collected from CP2-treated APP/PS1 mice
and measured using targeted metabolomics. n= 5 mice per group. All mice were 23-month-old. Data are presented as mean ± S.E.M. A two-way ANOVA
with Fisher’s LSD post-hoc test was used for data analysis. For the comparison between vehicle and CP2-treated APP/PS1 groups (b–f), an unpaired
Student t-test was used for statistical analysis. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
a) b) c) 
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Fig. 5 Chronic CP2 treatment improves synaptic activity and LTP in APP/PS1 mice. a Experimental setting for stimulation-evoked local field potential
(LFP) measurement in the hippocampal slice. The stimulation (Stim) electrode was placed at the Schaffer collaterals and the recording (Rec) electrode was
placed at the stratum radiatum in the CA1. Scale bar, 200 µm. b Representative raw traces of fEPSP from NTG and APP/PS1 mice. Various stimulation
intensities (10–300 µA) were applied to evoke fEPSP. The stimulation pulse width and intervals were fixed at 60 µs and 30 s, respectively. As the
stimulation intensity was increased, the initial slope of fEPSP was increased. c CP2 effect on basal synaptic strength. To examine the pre-post synaptic
relationships, initial slopes of fEPSP were plotted against amplitudes of presynaptic fiber volleys. Pre-post synaptic relationship in the CP2-treated APP/PS1
group was improved compared to the APP/PS1 group. d Paired-pulse facilitation did not differ between experimental groups. Two stimulations were
applied with a short interval to determine presynaptic involvement in synaptic plasticity. e CP2 treatment improves LTP formation. Average traces for
fEPSPs in hippocampal slices from each experimental group (n= 2–3 slices from 5 mice per group). Traces represent mean ± S.E.M. per time point. To
induce LTP, three tetanic stimulations (100 Hz, 60 µs-pulse width for 1 s) were applied with 3-sec intervals. In APP/PS1 hippocampus, the tetanic
stimulation induced early phase post-tetanic potentiation; however, long lasting potentiation was not observed. In the slices from APP/PS1 CP2-treated
mice, LTP was induced and maintained over 60min. NTG, black line; APP/PS1, orange line; NTG+ CP2, blue line; APP/PS1+ CP2, red line. f LTP intensities
among groups were compared at 60min (n= 3 slices from 5 mice per group).
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Fig. 6 CP2 treatment restores dendritic spine morphology and mitochondrial dynamics in the hippocampus of APP/PS1 mice. a Representative image of
3DEM reconstruction of axons (red) and dendrites (green, blue) from the CA1 hippocampal region of a NTG mouse. Reconstruction is superimposed on
2DEM from the same brain. Scale bar, 5 μm. b Representative 3DEM reconstructions of dendrites from CA1 region of NTG and APP/PS1 mice. Scale bar, 1
μm. c Quantification of dendritic spine morphology in vehicle and CP2-treated NTG and APP/PS1 mice. Mature dendritic spines included stubby,
mushroom and branched. d Quantification of active synapses visualized using 3DEM. e Western blot analysis in the hippocampal tissue assaying levels of
synaptophysin (Syn), BDNF, PSD95, TFAM, and SIRT3. f–j Quantification of proteins from e. k Representative 2DEM micrographs of mitochondria in the
hippocampus of CP2-treated and vehicle-treated APP/PS1 mice are used for quantifying mitochondrial morphology. l, m CP2 treatment increases the
number of elongated mitochondria and decreases the number of small organelles. n CP2 increased mitochondrial DNA copy number in NTG mice.
Data are presented as mean ± S.E.M. A two-way ANOVA with Fisher’s LSD post-hoc test was used. n= 5 per group. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001.
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neuronal network in APP/PS1 mice, which might be associated
with the reduction of Aβ accumulation and toxicity.
CP2 treatment activates translational neuroprotective
mechanisms essential for human AD. To investigate further
mechanisms associated with CP2 efficacy, we performed next-
generation RNA sequencing (RNA-seq) using brain tissue from
vehicle-treated or CP2-treated NTG and APP/PS1 mice (Fig. 8).
Principal component analysis (PCA) revealed a good separation
among all groups (Supplementary Fig. 13a). The comparison
between vehicle-treated NTG and APP/PS1 mice identified 3320
differentially expressed genes (DEGs) (Fig. 8a, Supplementary
Data 2). The top functional changes associated with these DEGs







































































































Fig. 7 CP2 treatment after the onset of AD-like neuropathology halts progressive degeneration of LC neurons in APP/PS1 mice. APP/PS1 and NTG
mice were treated with CP2 or vehicle starting at 10 months of age. The animal brains were harvested at 12 (2 months treatment) or 20 months of age
(10 months treatment) and evaluated for the integrity of the NAergic neurotransmitter system. a CP2 stops the progressive loss of TH+ axons in the cortex
of 20-month-old mice APP/PS1 mice. Representative images of TH+ axonal projections in S1BF. Scale bar, 20 µm. b The density (µm/mm3) of TH+ axons
in S1BF was determined using stereological length estimation using spherical probe and images presented in a. Compared to NTG mice, APP/PS1 mice
exhibit a significant progressive loss of TH+ axons at 12 and 20 months of age. CP2 treatment prevented loss of TH+ axons in APP/PS1 mice occurs
between 12 and 20 months of age. c Representative image of TH+ LC neurons in 20-month-old mice. Scale bar, 100 µm. d CP2 stops the progressive loss
of TH+ neurons in APP/PS1 mice in LC. e Higher magnification images from c were used to evaluate the relative sizes of neurons. Scale bar, 50 µm.
f CP2 stops the progressive loss of TH+ neuronal volume in APP/PS1 mice at 20 months of age. n= 6 female mice per group. Data are presented as mean
± S.E.M. A two-way ANOVA with Fisher’s LSD post-hoc test was used to analyze the differences between APP/PS1 mice, and between untreated groups
of NTG and APP/PS1 mice. A Student t-test was used to analyze the differences between untreated and CP2-treated NTG mice. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001.
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Fig. 13b. Processes affected by the disease in APP/PS1 mice
overlap with pathways well-established in AD patients including
ATP metabolism, ion transport, nervous system development,
synaptic transmission, and inflammation51–56 (Supplementary
Fig. 13b). Comparison of CP2-treated and vehicle-treated APP/
PS1 mice revealed changes in 1262 DEGs (Fig. 8a, Supplementary
Data 5). The top biological processes associated with these DEGs
included inflammatory response, redox signaling, nervous system
development, and regulation of axonal guidance (Supplementary
Fig. 13c–e, Supplementary Data 6, 7). Out of 3320 genes differ-
entially affected in vehicle-treated APP/PS1 vs. NTG mice, the
expression of 567 genes was reverted by CP2 treatment to the
levels detected in NTG mice (Fig. 8b, Supplementary Data 8). A
heatmap of changes in these 567 DEGs shows two clusters with a
subset of genes that were either downregulated or upregulated by
CP2 treatment (Fig. 8b, Clusters 1 and 2, Supplementary Data 9,
10). Gene function enrichment analysis showed that pathways
downregulated by CP2 in APP/PS1 mice included oxidative stress
and immune response (Supplementary Fig. 14d, e), consistent
with data generated in the brain and periphery of CP2-treated
APP/PS1 mice (Fig. 4).
Among genes involved in the regulation of oxidative stress and
apoptosis were G6pdx, BIRC3, TRIM30a, Trp53, and Mt3, all
known to play a role in human disease (Supplementary Fig. 14e).
Other important changes included global downregulation of the
immune response by CP2 including the acute phase response,
such as upregulation of SERPING1, interferon signaling (DDX58,
FCGR1A, TRIM25, GBP5, TLR7, IFITM3, IFIT1, NLRC5, OASL2,
IRGM1, IIGP1), and major histocompatibility complex (MHC)
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Fig. 8 Global gene expression patterns in brain tissue of APP/PS1 mice treated with CP2 relative to NTG and APP/PS1 mice. a Venn diagram of
differentially expressed genes (P < 0.05) in the brain tissue of vehicle-treated and CP2-treated NTG and APP/PS1 mice. Overlapped DEGs (567) represent
specific gene pools affected by CP2 treatment. b Heatmap of the overlapped 567 genes shows two clusters where CP2 treatment reversed (upregulated or
downregulated) the expression of a subset of genes in APP/PS1 mice to the levels observed in NTG littermates. Gene function enrichment analysis shows
pathways associated with downregulated (Cluster 1) or upregulated (Cluster 2) genes after CP2 treatment in APP/PS1 mice. c Pie diagrams showing the
number of downregulated (upper graph) and upregulated (lower graph) DEGs in vehicle-treated APP/PS1 mice that correlate with corresponding
downregulated or upregulated DEGs in the human AMP-AD dataset, respectively. d Enriched functions of downregulated DEGs in vehicle-treated APP/PS1
mice that correlate with the identified downregulated DEGs in the human AMP-AD dataset. e Enriched functions of upregulated DEGs in vehicle-treated
APP/PS1 mice that correlate with the identified upregulated DEGs in the human AMP-AD dataset. All mice were 23-month-old treated with CP2 or vehicle
for 13–14 months. NTG, n= 4 mice per group; APP/PS1 and APP/PS1+ CP2, n= 5 mice per group.
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01584-y ARTICLE
COMMUNICATIONS BIOLOGY |            (2021) 4:61 | https://doi.org/10.1038/s42003-020-01584-y | www.nature.com/commsbio 11
PSMB9) (Supplementary Fig. 14e). Pathways upregulated by CP2
included dendritic spine maturation, axonal extension and
guidance, and synaptic transmission (Supplementary Fig. 14f-g).
The identified upregulated genes in dendrite morphogenesis
pathways included the Down syndrome cell-adhesion molecule
(DSCAM) (Supplementary Fig. 14f), which is involved in
governing neurite arborization, mosaic tiling, and dendrite self-
avoidance and BTB Domain Containing 3 (BTBD3), which has a
role in dendritic guidance toward active axon terminals. Genes
that mediate axonogenesis, including Ntng1 and Ntng2, and
axonal guidance, were also upregulated in CP2-treated APP/PS1
mice (Supplementary Fig. 14g, Supplementary Fig. 13d). Addi-
tional genes upregulated by CP2 in APP/PS1 mice included those
involved in synaptic transmission and synapse assembly and that
are known to be downregulated in AD patients, including
glutamate receptor 4 (GRIA4), which mediates fast synaptic
excitatory neurotransmission; metabotropic glutamate receptor 7
and 2 (GRMN7 and GRM2), which facilitates the formation of
LTP; Double C2 protein (Doc2a), which contributes to sponta-
neous excitatory and inhibitory release; and Neurexins1
(NRXN1), which facilitates formation of functional synaptic
structures (Supplementary Figs. 13e, 14h). These data are
consistent with the improved synaptic function in CP2-treated
APP/PS1 mice (Fig. 5).
To provide further evidence for the translational potential of
our findings, we cross-validated transcriptomic data from our
study with the human brain transcriptome available through
coexpression meta-analysis across the Accelerating Medicines
Partnership in Alzheimer’s Disease Target Discovery and
Preclinical Validation Project (AMP-AD–ampadportal.org)57.
RNA-seq AMP-AD data were generated across three large scale
but distinct human postmortem brain studies collected from
2114 samples across 7 brain regions and 3 research studies54–56.
Since in our study we used only female mice, we restricted human
data to females only. We first correlated genetic changes found in
our comparison of NTG vs. APP/PS1 mice to significant DEGs
identified in comparison between the AD vs. control female
cohort in the AMP-AD set. Out of 3114 downregulated DEGs in
the human AD cohort (Supplementary Fig. 14a, Supplementary
Data 11), we identified 294 mouse DEGs that matched the human
gene set (Supplementary Data 12). Functional enrichment
analysis showed that the most downregulated pathways in both
human and mouse AD were involved in synaptic transmission,
nervous system development, histone deacetylation, and axono-
genesis (Supplementary Fig. 14b, Supplementary Data 13).
Downregulated shared genes in mouse and human AD included
genes involved in pyruvate metabolism such as MCP2, DLAT,
and PDHB (Supplementary Data 13). Among 518 upregulated
DEGs shared between human and mouse AD, top functions were
enriched for the innate immune response (Supplementary
Fig. 14a, c, Supplementary Data 14, 15). Thus, APP/PS1 mice
recapitulate major pathways affected in human AD.
We next compared the 567 DEGs associated with CP2
treatment in APP/PS1 mice (Fig. 8a) with DEGs from females
in the AMP-AD RNA-seq data collection. We found that 128 out
of the total 567 overlapping mouse AD DEGs corresponded to
human AD genes (Fig. 8c). CP2 treatment in APP/PS1 mice
reversed the expression of 71 genes that were upregulated in both
mouse and human AD (Supplementary Data 16). Functional
enrichment analysis showed that these 71 genes were involved in
the regulation of the immune processes, inflammation, response
to reactive oxygen species, and TNF production (Fig. 8d,
Supplementary Data 17). In contrast, CP2 reversed the expression
of 57 deregulated genes that are involved in axonogenesis,
glutamatergic synaptic transmission, nervous system develop-
ment, and synapse assembly (Fig. 8c, e and Supplementary
Data 18, 19). Taken together, these data demonstrate that AD-
associated transcriptional and functional changes observed in our
mouse model of AD are counteracted by CP2 treatment. CP2-
treated APP/PS1 mice showed attenuated expression of a number
of genes involved in neuroinflammatory processes, consistent
with our observation of a decreased number of activated
astrocytes and microglia. Moreover, CP2 treatment of APP/PS1
mice restored expression of genes involved in neurotransmission,
dendritic morphology and axonal guidance and extension, which
were linked to the restoration of hippocampal LTP and increased
number of mature dendritic spines (Fig. 6). These data
demonstrate that pathways improved by CP2 treatment in
APP/PS1 mice comprise major pathways essential for therapeutic
efficacy in AD patients.
Discussion
AD is associated with early energy hypometabolism, synaptic and
mitochondrial dysfunction, oxidative stress, inflammation,
abnormal proteostasis and progressive neurodegeneration. Here,
we demonstrate that mild energetic stress associated with partial
inhibition of MCI induces activation of integrated stress-response
mechanisms that attenuate effects of pathological pathways such
as abnormal energy homeostasis, synaptic dysfunction, and
inflammation, ultimately blocking neurodegeneration in a trans-
lational mouse model of AD, the APP/PS1 mice. The therapeutic
efficacy achieved has translational relevance, as the intervention
was started after the onset of Aβ neuropathology26, cognitive
symptoms27, bioenergetic dysfunction28, and progressive neuro-
degeneration. Beneficial mechanisms affected by CP2 treatment
in APP/PS1 mice overlap with signatures established in AD
patients, females in particular, supporting the high translational
potential of this approach. Major translational targets affected by
CP2 treatment included the immune system response and mul-
tiple pathways involved in synaptic function and neuro-
transmission, which underlie early pathology in AD patients8.
Since CP2 improved axonogenesis and dendritic spine mor-
phology and function, it is feasible that this treatment could also
induce neuronal regeneration.
The strength of our study is in the utilization of multiple early
and late disease outcome measures in a mouse model of AD that
closely mimics neuropathological mechanisms of human disease.
In particular, we hypothesized that the general failure of the
preclinical studies in mouse models of AD to predict outcomes of
human clinical trials is related to the reliance on treatments of
younger mice and a very limited set of neuropathological out-
come measures. Thus, it is important that CP2 treatment of APP/
PS1 mice was conducted when AD-like pathology, including
progressive neurodegeneration, was well established and the
broad array of measures, including advanced imaging techniques
and translational biomarkers, were applied in vivo and in tissue,
further supporting the ability to monitor therapeutic efficacy of
this approach in humans. However, this study was limited only to
female mice.
While the details and the hierarchy of molecular mechanisms
involved in neuroprotective stress response require further eva-
luation, AMPK activation appears to play a central role. Indirect
activation of AMPK by inhibition of MCI has been shown to
increase life span, rejuvenate the transcriptome, and protect from
neurodegeneration58–62. Paradoxically, these manipulations
improved MCI assembly, increased complex I-linked state 3
respiration, and decreased ROS production59. Studies in a cohort
of 2200 ultranonagenarians revealed that mutations in subunits of
MCI that resulted in its partial inhibition had beneficial effect on
longevity63. The compelling support for safety of the application
of MCI inhibitors in humans comes from metformin, an FDA
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approved drug to treat diabetes. Among other targets, metformin
inhibits MCI. It is prescribed to the elderly population and has
relatively safe profile even after chronic treatment64. Recent study
conducted in a large Finish population of older people with
diabetes demonstrated that long-term and high-dose metformin
use does not increase incidences of AD and is associated with a
lower risk of developing AD65. Resveratrol is another MCI
modulator where its effect on MCI (activation or inhibition)
depends on the concentration. It also inhibits mitochondrial
Complex V. Resveratrol is currently in clinical trials for multiple
human conditions66–68. Compared to CP2, these compounds
have limitations associated with the lack of selectivity, specificity,
and bioavailability.
CP2 treatment effectively reduced Aβ accumulation. This
might be explained by an additional ability of CP2 to bind Aβ
peptides reducing their toxicity, which together with the AMPK-
dependent mechanisms, could produce a synergistic effect69. Our
work also provides evidence that CP2 treatment improves mito-
chondrial dynamics and function. While counterintuitive, given
that progressive mitochondrial dysfunction is well characterized
in AD patients and APP/PS1 mice, mild MCI inhibition in dys-
functional mitochondria could decrease ROS production, while in
functional mitochondria could improve energetics, as we
demonstrated previously69, and through activation of stress
responses, could promote biogenesis and mitophagy, contributing
to a healthier mitochondrial pool and more effective energy
production. Positive effects on mitochondrial function and neu-
roprotection are further supported by an increase in Sirt3 levels.
In AD patients and AD models, reduction of Sirt3 was directly
linked to the loss of synaptic function, Aβ and Tau pathology, and
neurodegeneration20,21,44. While APP/PS1 mice utilized in our
study do not have pTau accumulation, increased levels of Sirt3
and decreased activity of GSK3β suggest that CP2 treatment
could also be effective in reducing Tau toxicity. Indeed, our
independent study in the mouse model of AD that along with the
mutant human APP and PS1 proteins also expresses mutant
human Tau protein, the 3xTg-AD mice70, demonstrated that
chronic CP2 treatment reduced pTau levels and improved LTP
and energy homeostasis in symptomatic male and female mice.
While this study interrogated CP2 efficacy only in female APP/
PS1 mice, treatment in 3xTg-AD mice was beneficial in males and
females. These data further support the concept that targeting
mitochondria with small molecule specific MCI inhibitors
represents a promising strategy that could be efficacious in
patients with synergistic Aβ-related and pTau-related pathology.
While not as pronounced as in APP/PS1 mice, CP2 treatment
improved health parameters in aged NTG mice, reducing oxi-
dative stress and cellular senescence, key pathways that accelerate
aging, and improving body mass, glucose tolerance, mitochon-
drial function, and physical strength. Taken together, the results
of our studies suggest that partial inhibition of MCI represents a
novel treatment strategy for blocking neurodegeneration and
cognitive impairment, even after the development of AD-like
symptoms, and also could enhance healthspan delaying the onset
of multiple age-related diseases, including AD.
Methods
All experiments with mice were approved by the Mayo Clinic Institutional Animal
Care and Use Committee in accordance with the National Institutes of Health’s
Guide for the Care and Use of Laboratory Animals. IACUC Protocol A00001186-
16-R18.
CP2 synthesis. CP2 was synthesized by the Nanosyn, Inc biotech company (http://
www.nanosyn.com) as described71 and purified using HPLC. Authentication was
through NMR spectra to ensure the lack of batch-to-batch variation in purity. CP2
was synthesized as free base. For in vitro experiments, CP2 was prepared as 50 mM
stock solution in PEG400. Stock aliquots of 20 μl were stored at −80 °C. Each
aliquot was used once to avoid freeze-though cycle. Preparation of CP2 for mouse
treatment via drinking water is described below.
Mice. The following female mice were used in the study: double transgenic APP/
PS172 and their non-transgenic (NTG) littermates; CD-1 and C57BL/6J wild-type
mice. Genotypes were determined by PCR as described in ref. 72. All animals were
kept on a 12 h–12 h light–dark cycle, with a regular feeding and cage-cleaning
schedule. Mice were randomly selected to study groups based on their age and
genotype. Mice were housed 5 per cage, water consumption and weight were
monitored weekly. CP2 concentration was adjusted based on mouse weight/water
consumption weekly. The number of mice in each group was determined based on
the 95% of chance to detect changes in 30–50% of animals. The following exclusion
criteria were established: significant (15%) weight loss, changing in the grooming
habits (hair loss), pronounced motor dysfunction (paralyses), or other visible signs
of distress (unhealed wounds).
Human brain tissue. Experiments with post-mortem human brain tissue were
approved by the Mayo Clinic IRB (#12-007847) and were carried out in accordance
with the approved guidelines. Informed consent was obtained from all subjects
involved in the study. One brain specimen with a postmortem interval of 6 h from
a cognitively normal female 99 years old was obtained from Mayo Clinic. Cortex
was used for mitochondrial isolation to determine CP2-dependent inhibition
of MCI.
Mitochondrial isolation and measurements of ETC complex activity. Intact
brain mitochondria were isolated from post-mortem human or mouse brain tissue
using differential centrifugation with digitonin treatment73. Brain tissue was
immersed into ice-cold isolation medium (225 mM mannitol, 75 mM sucrose,
20 mM HEPES-Tris, 1 mM EGTA, pH 7.4), supplemented with 1 mg/ml BSA.
Tissue was homogenized with 40 strokes by pestle “B” (tight) of a Dounce
homogenizer in 10 ml of isolation medium, diluted two-fold, and transferred into
centrifuge tubes. The homogenate was centrifuged at 5900 × g for 4 min in a
refrigerated (4 °C) Beckman centrifuge. The supernatant was centrifuged at
12,000 × g for 10 min and pellets were resuspended in the same buffer, and 0.02%
digitonin was added. The suspension was homogenized briefly with five strokes in a
loosely fitted Potter homogenizer and centrifuged again at 12,000 × g for 10 min,
then gently resuspended in the isolation buffer without BSA and washed once by
centrifuging at 12,000 × g for 10 min. The final mitochondrial pellet was resus-
pended in 0.1 ml of washing buffer and stored on ice. The respiratory activities
were measured in Oroboros high-resolution respirometer as previously
described74.
The activity of the ETC complexes was measured spectrophotometrically using a
plate reader (SpectraMax M5, Molecular Devices, USA) in 0.2ml of standard
respiration buffer composed of 125mM sucrose, 25 mM Tris-HCl (pH= 7.5), 0.01
mM EGTA, and 20mM KCl at 25 °C. NADH-dependent activity of complex I was
assayed as oxidation of 0.15 mM NADH at 340 nm (ε340 nm= 6.22mM−1cm−1) in
the assay buffer supplemented with 10 µM cytochrome c, 40 µg/ml alamethicin,
1 mM MgCl2 (NADH media). NADH:Q reductase was measured in NADH media
containing 2mg/ml BSA, 60 µM decylubiquinone, 1 mM cyanide and 5–15 µg
protein per well. Only the rotenone (1 µM)-sensitive part of the activity was used for
calculations. NADH:HAR reductase was assayed in NADH media containing 1mM
HAR and 2–5 µg protein per well. Complex II succinate:DCIP reductase activity was
recorded at 600 nm (ε600 nm= 21mM−1cm−1) in the KCl assay buffer (125mM
KCl, 20mM HEPES-Tris, 0.02 mM EGTA, pH 7.6) containing 15mM succinate, 40
µM decylubiquinone, 0.1 mM DCIP, 1 mM KCN, and 5–10 µg protein per well.
Complex IV ferrocytochrome c oxidase activity was measured as oxidation of 50 µM
ferrocytochrome c at 550 nm (ε550 nm= 21.5 L ∙mM−1cm−1) in KCl assay buffer
supplemented with 0.025% dodecylmaltoside and 1–3 µg protein per well. To assess
the effect of CP2 on the activity, we pre-incubated 20–40 µg/ml mitochondria with
various concentrations of CP2 for 10min at 25 °C in the absence of substrates and
then measured the residual activity as described above.
In vitro pharmacology studies. CP2 binding and enzyme and uptake assays were
conducted by the Contract Research Organization (CRO) Eurofins Cerep (France).
CP2 was tested at 10 μM. Compound binding was calculated as a % inhibition of
the binding of a radioactively labeled ligand specific for each target. Compound
enzyme inhibition effect was calculated as a % inhibition of control enzyme
activity. In each experiment and if applicable, the respective reference compound
was tested concurrently with the test compounds, and the data were compared with
historical values determined at Eurofins. The experiment was accepted in accor-
dance with Eurofins validation Standard Operating Procedure. Results showing an
inhibition (or stimulation for assays run in basal conditions) higher than 50% are
considered to represent significant effects of the test compounds. 50% is the most
common cut-off value for further investigation (determination of IC50 orEC50
values from concentration-response curves). Results showing an inhibition (or
stimulation) between 25 and 50% are indicative of weak to moderate effects (in
most assays, they should be confirmed by further testing as they are within a range
where more inter-experimental variability can occur). Results showing an inhibi-
tion (or stimulation) lower than 25% are not considered significant and mostly
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attributable to variability of the signal around the control level. Low to moderate
negative values have no real meaning and are attributable to variability of the signal
around the control level. High negative values (≥50%) that are sometimes obtained
with high concentrations of test compounds are generally attributable to non-
specific effects of the test compounds in the assays. On rare occasion they could
suggest an allosteric effect of the test compound. Binding Assays. The results are
expressed as a percent of (control specific binding/measured specific binding) × 100
control specific binding and as a percent inhibition of control specific binding (100
− (measured specific binding/control specific binding) × 100 obtained in the pre-
sence of the test compounds. The IC50 values (concentration causing a half-
maximal inhibition of control specific binding) and Hill coefficients (nH) were
determined by non-linear regression analysis of the competition curves generated
with mean replicate values using Hill equation curve fitting Y=D+ [(A−D/1+
(C/C50)nH] where Y= specific binding, A= left asymptote of the curve, D= right
asymptote of the curve, C= compound concentration, C50= IC50, and nH=
slope factor. This analysis was performed using software developed at Cerep (Hill
software) and validated by comparison with data generated by the commercial
software SigmaPlot® 4.0 for Windows® (© 1997 by SPSS Inc.). The inhibition
constants (Ki) were calculated using the Cheng Prusoff equation Ki= (IC50/(1+ L/
KD) where L= concentration of radioligand in the assay, and KD= affinity of the
radioligand for the receptor. A scatchard plot is used to determine the KD. Enzyme
and Uptake Assays. The results are expressed as a percent of control specific
activity: (measured specific activity/control specific activity) × 100 and as a percent
inhibition of control specific activity 100-(measured specific activity/control spe-
cific activity × 100) obtained in the presence of the test compounds. This analysis
was performed using software developed at Cerep (Hill software) and validated by
comparison with data generated by the commercial software SigmaPlot® 4.0 for
Windows® (© 1997 by SPSS Inc.).
250 kinase panel kinase panel. Nanosyn, Inc (Santa Barbara, CA, http://www.
nanosyn.com.) was contracted to conduct Kinome Wide panel (KWP) screening
against 250 kinases. CP2 was tested at 1 and 10 μM concentrations. The buffer
components and assay conditions differ based on the specific assay. The assay has a
total volume of 10 µL comprised of 5 µL enzyme buffer and 5 µL substrate buffer.
After incubation and termination, substrate and product are separated and
quantified electrophoretically using the microfluidic-based LabChip 3000 Drug
Discovery System from Caliper Life Sciences. ADP Glo is another method of





3. Reaction termination and data generation
Compound management. Compounds are plated at 100× of the screening con-
centrations on a Labcyte compatible plate along with 3 reference compounds.
Assay setup. Add 5 µl/well of enzyme buffer to the 384-well assay plate except
control wells where buffer without enzyme are added. Using Labcyte Echo 550,
transfer 100 nl of compounds to the assay plate. Add 5 µl/well of substrate buffer to
the assay plate. Incubate the reaction mixture at 25 °C according to the assay
specific incubation time.
Reaction termination and data generation. For Mobility Shift assay, the reaction is
terminated by addition of EDTA buffer and the assay plate is read on Caliper
LabChip 3000.
For ADP Glo based assay, the reaction is terminated by applying the Promega
ADP Glo Kinase Assay kit and the assay plate is read on a LJL Biosystems
Analyst HT.
In vivo CP2 pharmacokinetic. CP2 bioavailability was determined using C57BL/6J
female mice ordered from the Jackson Laboratory. Mice were acclimatized for one
week to the new environment prior to initiation of experiments. For evaluating
CP2 concentrations in plasma, mice were injected with a single intravenous (IV)
dose of CP2 (3 mg/kg in DMSO) in a lateral tail vein using a 0.5 cc tuberculin
syringe. An independent cohort of mice was administered CP2 by oral gavage (PO)
(25 mg/kg in 20% PEG 400 and 5% dextrose water in PEG) with a 1 cc tuberculin
syringe with a stainless steel 22 gauge straight feeding needle. At 0, 0.08, 0.25, 0.5, 1,
2, 4, 8, and 24 h after treatment, mice were anesthetized, and 200 µl of blood was
collected from the retro-orbital sinus through a K2EDTA coated capillary into a
K2EDTA coated microtainer tube. Plasma was separated by centrifugation at 4 °C
(10,000 rpm × 3min), transferred to a microcentrifuge tube, immediately frozen on
dry ice, and stored at −80 °C until the analysis. Pharmacokinetic parameters for
CP2 were estimated with standard non-compartmental analysis. Pharmacokinetic
parameters for plasma were estimated using the concentration–time profiles for
each route of administration, IV or PO (Supplementary Fig. 4). The apparent
elimination half-life (T1/2) was calculated using a pharmacokinetics half-life
program on a RS/1 computer system. The area under the plasma
concentration–time curve (AUC) from time 0 to infinite time (AUC (0-inf)) was
determined by conventional trapezoidal summation and extrapolation. The max-
imum plasma CP2 concentration (Cmax) and the time of maximum plasma CP2
concentration (Tmax) were read directly from the plotted data. The AUC (0–24 h)
represents the area under the plasma concentration-time curve over the last 24 h
dosing interval; the AUC (0-inf), area under the plasma concentration-time curve
to infinity represents the total drug exposure across time. CI/F, apparent total
clearance of the drug from plasma after oral administration and F represents the
drug bioavailability. The PO availability of CP2 is 65%.
CP2 quantification using LC-MS/MS. Paclitaxel (Sigma, St. Louis, MO) was used
as an internal standard (IS). Ultra-pure water was generated using a Barnstead
nanopure diamond system (Thermo, Marietta, OH). Optima LC/MS-grade
methanol (MeOH, Fisher Scientific, Waltham, MA), analytical grade formic acid
(Fisher Scientific, Waltham, MA), 96 well protein crash plates and 1 ml 96 well
polypropylene collection plates (Chromtech, Apple Valley, MN), Kunststoff-
Kapillaren end-to-end K2EDTA coated plastic 30 µl capillary tubes (Fisher Scien-
tific, Waltham, MA) and K2EDTA presprayedmicrotainer collection tubes (500 µl,
Becton, Dickinson and Company, Franklin Lakes, NJ) were utilized in this study.
For controls, drug-free mouse plasma was obtained from healthy CD-1 mice
containing 0.1% K2EDTA that was purchased from Valley Biomedical and stored at
−20 °C for later use. The LC-MS/MS consisted of a Waters Acquity H class ultra-
performance liquid chromatography (UPLC) system containing a quaternary sol-
vent manager and sample manager-FTN coupled to a Xevo TQ-S mass spectro-
meter equipped with an electrospray ionization (ESI) source. Data were acquired
and analyzed using Waters MassLynx v4.1 software. Detection of CP2 and pacli-
taxel (internal standard, IS) was accomplished by multiple reaction monitoring
(MRM) using the mass spectrometer in positive ESI mode with capillary voltage,
2.5 kV; source temperature 150 °C; desolvation temperature 400 °C; cone gas flow
150 L/h; desolvation gas flow 800 L/h. The cone voltages and collision energies for
CP2 and paclitaxel were determined by MassLynx-Intellistart v4.1 software and
were 12 and 18 V (cone) and 30 and 66 eV (collision), respectively. MRM precursor
and product ions were monitored at m/z 394.41 > 139.19 for CP2 and 854.29 >
105.08 for paclitaxel. Data were collected from 2–5.5 for both CP2 and paclitaxel.
The separation of CP2 and paclitaxel was achieved using an Agilent Poroshell 120
EC-C18 (2.7 µ, 2.1 × 100 mm) with an Agilent EC-C18 pre-column (2.7 µ, 2.1 × 5
mm) and a gradient elution program containing ultra-pure water and MeOH, both
with 0.1% formic acid. The gradient begins with 70% aqueous, decreases to 10%
aqueous over 3 min and holds there for 2 min, then returns to baseline over 0.1 min
and holds to equilibrate for 2.9 min. The flow rate was 0.4 ml/min, the total run
time was 8 min, injection volume was 5 µl, and the column and auto sampler
temperatures were 40 °C and 20 °C, respectively. Stock solutions of CP2 (5 mg/ml,
dissolved in DMSO) and paclitaxel (200 ng/ml, dissolved in acetonitrile, ACN)
were prepared in salinized glass vials and stored at −20 °C. 20× working stock
solutions were prepared daily and diluted in 1:1 MeOH:H2O and stored at −20 °C.
Plasma standards containing CP2 (0.2–100 ng/ml) were prepared by adding (5 µl)
aliquots of 20× CP2 to plasma (95 µl) in 1.5 ml slick microfuge tubes, 50 µl of this
plasma dilution were transferred to a 96 well protein crash plate. Analytes were
isolated using protein precipitation with 150 µl ACN containing IS (200 ng/ml).
The plate was capped and shaken for 20 min at 1100 rpm. The sample was then
vacuum filtered into a Chromtech (Apple Valley, MN) 1 ml 96 well polypropylene
collection plate, evaporated to dryness under a gentle stream of nitrogen, and
reconstituted with 200 µl H2O/ACN (1:1). The collection plate was capped and
shaken at 900 rpm for 20 min, and 5 µl aliquots were injected into the LC/MS/MS.
Mass Spectra and ion chromatograms of CP2 and IS were processed using Mas-
sLynx v4.1 software with TargetLynx. Standard curves for CP2 and paclitaxel were
analyzed using the peak area ratio of CP2 vs. IS. CP2 standard curve concentrations
were 0.2, 0.5, 1, 5, 10, 20, 50, and 100 ng/ml. The concentration of CP2 in the brain
was determined using the same approach.
Acute CP2 treatment in symptomatic APP/PS1 mice. A cohort of 9–10-month-
old female APP/PS1 mice was treated with CP2 (25 mg/kg in 20% PEG 400 and 5%
dextrose water in PEG) by oral gavage. Mice were sacrificed at 0, 4, 24, 48, and 72 h
(n= 1 per time point), and Western blot analysis was conducted in the hippo-
campal tissue to determine the engagement of neuroprotective mechanisms. In an
independent cohort of 9–10-month-old female and male APP/PS1 mice and their
NTG controls (n= 3 mice per group), baseline glucose uptake was measured at 0 h
and after CP2 gavage (25 mg/kg in 20% PEG 400 and 5% dextrose water in PEG) at
24, 48, and 72 h using in vivo FDG-PET as discussed below.
In vivo FDG-PET. Mice were fasted one hour prior to I. P. injection of 270 uCi of
fludeoxyglucose F18 (18FDG) in 200 μl injection volume prepared the same day at
the Mayo Clinic Nuclear Medicine Animal Imaging Resource. Imaging was con-
ducted 30 min post injection. Prior to imaging, mice were individually placed in an
anesthesia machine (Summit Medical Equipment Company, Bend, Oregon) and
anesthetized with 4% isoflurane with 1–2 LPM oxygen. Anesthesia was further
maintained with 2% isoflurane delivered by a nose cone. Mice were placed in
MicroPET/CT scanner (Scanner Inveon Multiple Modality PET/CT scanner,
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Siemens Medical Solutions USA, Inc.). Mouse shoulders were positioned in the
center of the field of view (FOV), and PET acquisition was performed for 10 min.
CT scanning parameters were as following: 360 degree rotation; 180 projections;
Medium magnification; Bin 4; Effective pixel size 68.57; Tranaxial FOV 68 mm;
Axial FOV 68mm; 1 bed position; Voltage 80 keV; Current 500 µA; Exposure
210 ms. CT reconstruction parameters: Alogorithm: Feldkamp, Downsample 2,
Slight noise reduction with application of Shepp-Logan filter. A final analysis was
done using PMOD Biomedical Image Quantification and Kinetic Modeling Soft-
ware, (PMOD Technologies, Switzerland). The volume of interest (VOI) was
created on the CT image of the entire brain. The VOI was applied to the corre-
sponding registered PET scan. The volume statistics were recorded. The percentage
of brain glucose uptake was calculated by correcting the measured concentration of
uCi recorded after 30 min to the amount of injected dose.
Chronic CP2 treatment in NTG and symptomatic APP/PS1 mice. NTG and
APP/PS1 female mice (n= 16–21 per group) were given either CP2 (25 mg/kg/day
in 0.1% PEG dissolved in drinking water ad lib) or vehicle-containing water (0.1%
PEG) starting at 9 months of age as we described in ref. 14. Mice were housed 5 per
cage, water consumption and weight were monitored weekly. CP2 concentration
was adjusted based on mouse weight/water consumption weekly. Independent
groups of mice were continuously treated for 14 months until the age of 23 months.
Seven to eight months after CP2 treatment, mice were subjected to the battery of
behavior tests, metabolic cages (CLAMS), FDG-PET, 31P NMR spectroscopy, and
electrophysiology. After mice were sacrificed, tissue and blood were subjected to
Western blot analysis, profiling for cytokines/chemokines, next-generation RNA
sequencing, immunohistochemistry, electron microscopy examination, and meta-
bolomics as described below.
Behavior battery. Behavioral tests were carried out in the light phase of the
circadian cycle with at least 24 h between each assessment as we described pre-
viously13. More than one paradigm ran within 1 week. However, no more than two
separate tests were run on the same day. Behavioral and metabolic tests were
performed in the order described in the experimental timeline. Open field test.
Spontaneous locomotor activity was measured in brightly lit (500 lux) Plexiglas
chambers (41 cm × 41 cm) that automatically recorded the activity by photo beam
breaks (Med Associates, Lafayette, IN). The chambers were located in sound-
attenuating cubicles and were equipped with two sets of 16 pulse-modulated
infrared photo beams to automatically record X–Y ambulatory movements at a
100 ms resolution. Data was collected over a 100-min trial at 30-s intervals.
Hanging bar. Balance and general motor function were assessed using the hanging
bar. Mice were lowered onto a parallel rod (D < 0.25 cm) placed 30 cm above a
padded surface. Mice were allowed to grab the rod with their forelimbs, after which
they were released and scored for success (pass or failure) in holding onto the bar
for 30 s. Mice were allowed three attempts to pass the test. Any one successful
attempt was scored as a pass. The final score was presented as an average of three
trials per animal. Rotarod test. The accelerating rotarod (UgoBasile, Varese, Italy)
was used to test balance and coordination. It comprised of a rotating drum that
accelerated from 5 to 40 rpm over a 5-min periods. The latency of each animal to
fall was recorded and averaged across three consecutive trials. Novel Object
Recognition test (NOR) was used to estimate memory deficit. All trials were con-
ducted in an isolated room with dim light in Plexiglas boxes (40 cm × 30 cm). A
mouse was placed in a box for 5 min for acclimatization. Thereafter, a mouse was
removed, and two similar objects were placed in the box. Objects with various
geometric shape and color were used in the study. Mice were returned to the box,
and the number of interrogations of each object was automatically recorded by a
camera placed above the box for 10 min. Mice were removed from the box for 5
min, and one familiar object was replaced with a novel object. Mice were returned
to the box, and the number of interrogations of novel and familiar objects was
recorded for 10 min. Experiments were analyzed using NoldusЕthoVision software.
The number of interrogations of the novel object was divided by the number of
investigations of the familiar object to generate a discrimination index. Intact
recognition memory produces a discrimination index of 1 for the training session
and a discrimination index greater than 1 for the test session, consistent with
greater interrogation of the novel object. Morris Water Maze (MWM). Spatial
learning and memory were investigated by measuring the time it took each mouse
to locate a platform in opaque water identified with a visual cue above the platform.
The path taken to the platform was recorded with a camera attached above the
pool. Each mouse was trained to find the platform during four training sessions per
day for three consecutive days. For each training session, each mouse was placed in
the water facing away from the platform and allowed to swim for up to 60 s to find
the platform. Each training session started with placing a mouse in a different
quadrant of the tank. If the mouse found the platform before the 60 s have passed,
the mouse was left on the platform for 30 s before being returned to its cage. If the
animal had not found the platform within the 60 s, the mouse was manually placed
on the platform and left there for 30 s before being returned to its cage. A day of
rest followed the day of formal testing.
Intra-peritoneal (IP) glucose tolerance test (IPGTT). The glucose tolerance test
measures glucose clearance after it was delivered using IP injection. Mice were
fasted for approximately 16 h, and fasted blood glucose levels were determined
before a solution of glucose was administered by IP injection. Subsequently, the
blood glucose level was measured at different time points during the following 2 h
(0, 20, 30, 60, and 120 min after the injection). Mice were injected with 20% glucose
solution based on the body weight (2 g of glucose/kg body weight).
Intra-peritoneal (IP) insulin sensitivity test (IPIST). The insulin sensitivity test
measures glucose clearance after insulin is delivered using IP injection. Mice were
fasted for approximately 5 h, and fasted blood glucose levels were determined
before a solution of insulin (diluted in saline) was administered by IP injection.
Subsequently, the blood glucose level was measured at different time points during
the following 2 h (0, 20, 30 60, 90, and 120 min after the injection). Mice were
injected with 0.5 U/ml insulin solution based on the body weight (0.5 U/kg).
Aβ ELISA. Levels of Aβ40 and Aβ42 were determined in brain tissue from 23-
month-old APP/PS1 mice treated for 14 months with CP2 (n= 9) or vehicle (n=
9). Differential fractionation was achieved by collecting fractions with most to least
soluble Aβ40 and Aβ42 from brain tissue sequentially homogenized in Tris-
buffered saline (TBS, most soluble); in TBS containing 1% Triton X-100 (TBS-TX),
and 5M guanidine in 50 mM Tris-HCl (least soluble), pH 8.0 as described in ref. 13.
Levels of human Aβ40 and Aβ42 were determined by ELISA using antibodies
produced in-house as previously published75.
Immunohistochemistry. We followed a protocol described previously50. Briefly,
for histological analysis, mice were perfused intracardially with 4% paraf-
ormaldehyde. Brains were cryoprotected, and serial frozen coronal sections (40 μm)
were serially distributed into individual wells of 12-well plates. To facilitate the
identification of regions of interest for the quantitative stereological analysis, every
24th section through the entire brain was Nissl stained and compared with the
stereotaxic coordinates of the mouse brain76. To detect antigens of interest, the
sections were incubated in primary antibodies followed by the ABC method
(Vector Laboratories) using 3,3’-diaminobenzidine (DAB, Sigma Alrich) as the
chromogen for visualization. Antigen retrieval was performed using a Rodent
Decloaker for all samples, with an additional 88% formic acid pre-treatment for
4G8-incubated samples. Primary antibodies used are: tyrosine hydroxylase (TH)
antibody (rabbit polyclonal, Millipore) for noradrenergic (NAergic) neurites/axons;
4G8 anti-Aβ mouse monoclonal antibody (Biolegend) for amyloid deposits; anti-
GFAP rabbit polyclonal antibody (Dako) for astrocytes; and anti-Iba1 rabbit
polyclonal antibody (Wako) for microglia. NA and dopaminergic (DA) fibers/
neurons were visualized using an anti-tyrosine hydroxylase (TH) antibody (Novus
Biologicals). Cresyl violet (CV) was used to stain for nuclei of non-MAergic
neurons for neuronal counts.
Stereological analysis of Aβ deposition and glial reaction. All stereological
analysis was performed using the StereoInvestigator software (MicroBrightField,
Colchester, VT)49,50. Extent of brain area covered by amyloid deposits (4G8
immunostained area), astrocytes (GFAP), or microglia (Iba1) was measured within
the regions of interests (ROI) using the area fraction analysis49. The ROIs traced
using The Mouse Brain in Stereotaxic Coordinates77 included the barrel field region
of primary somatosensory cortex (S1BF; sections between bregma −0.10 to −1.22
mm, posterior to the anterior commissure and anterior to hippocampus) and
dorsal hippocampus (dentate, CA1, CA2/3; sections between bregma −1.46 to
−2.18 mm); the S1 barrel cortex (S1BF) and dorsal hippocampal regions. For each
mouse, every 12th coronal brain sections (4–6 sections) containing the ROIs were
immunostained. The sections were analyzed using Stereo Investigator (MBF
Bioscience, Williston, VT), with a ×40 objective, where the ROIs were outlined, and
the Area Fraction Fractionator probe was used to systematically and randomly
allocate sampling sites 400 μm apart in the cortex, and 200 μm apart in the hip-
pocampus. At each sampling site, a 100 × 80 μm counting frame was superimposed,
containing markers equally spaced from one another at a distance of 15 μm. The
area fraction markers that overlap with immunoreactive tissue were labeled as
positive, whereas remaining markers were labeled negative. Because the ratio of
untainted and stained markers is proportional to the areas occupied, we calculated
the percent of total area that was immunostained. Representative images are
included in the paper. The actual immunostained brain sections for additional
analysis or examination could be available upon request directed to Dr. M. Lee.
Stereological analysis of NAergic afferents and neurons. To determine the
length of NAergic axons, we used stereological length estimation with spherical
probes (Stereo Investigator; MicroBrightField)50. Because the densities of NAergic
afferents show substantial regional variation, we focused our analysis on the
selected subregions or ROIs (S1BF and dorsal hippocampus) for NAergic afferents.
Every eighth section, starting from a start of the ROI regions through the entire
ROI region of interest, slices were processed for immunocytochemistry. To
determine the axon length, virtual spherical probes were placed within a 40 μm
thick section. At each focal plane, concentric circles of progressively increasing and
decreasing diameters were superimposed, and the intersections with the immu-
noreactive fibers and circles were counted (Q). To minimize surface artifacts, a
guard volume of 1 μm was used. This method allows for the simple determination
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of the total length density (LV) and the total length (L). To reduce the effects of
variations in the area selection, LV was routinely used for comparison between
groups. The axon lengths were measured at 50 random locations through the
reference space.
To determine the total number of NAergic neurons in the LC, we used the
optical fractionator78. Every 4th section of the entire region containing the LC was
immunostained for TH and counterstained with CV. Total TH+ and TH− neuron
numbers were estimated using the optical fractionator probe; the LC region of
interest was traced and magnified using the ×100 objective, and TH+ neurons and
TH− nuclei were counted using the counting frame of 40 × 30 μm a 1 μm guard, a
130 × 130 μm sampling grid, and a dissector height of 10 µm.
For unbiased stereological analysis of neuronal size (area and volume), we used
the nucleator feature of the Stereology software50,78. Neurons were randomly
sampled within the sections used for neuron counts and, using the nucleator
feature of the software, we determined neuron volumes by placing four rays
through the cell, with the nucleolus serving as the midpoint. The cells were
measured if their nuclear membrane intersected or touched the inclusion (green)
line. The cells were excluded if the nuclear membrane intersected or touched the
exclusion (red) line. The measuring rays were “cut” at the intersection with the cell
membrane. If a ray extended into a dendrite, the ray was “cut” at the base of the
dendrite. Representative images are included in the paper. Representative images
are included in the paper. The actual stained brain sections for additional analysis
or examination could be available upon request directed to Dr. M. Lee.
Inflammatory markers. After 16 h of fasting, blood from 23-month-old APP/PS1
and NTG mice that had been treated for 14 months with CP2 (n= 15–20 per
group) or vehicle (n= 15–20 per group) was collected by orbital bleed and cen-
trifuged for 10 min at 2500 rpm. Collected plasma was sent for 32-plex cytokine
array analysis (Discovery Assay, Eve Technologies Corp. https://www.
evetechnologies.com/discovery-assay/). The multiplexing analysis was performed
using the Luminex 100 system (Luminex). More than 80% of the targets were
within the detectable range (signals from all samples were higher than the lowest
standard). For the data that were out of range (OOR<), their values were desig-
nated as 0 pg/ml. Blood samples were run in duplicates.
Lipid peroxidation assay. Levels of malondialdehyde (MDA), a product of lipid
degradation that occurs as a result of oxidative stress, were measured using an
MDA assay kit (#MAK085, Sigma Aldrich) in hippocampal brain tissue isolated
from 23-month-old APP/PS1 and NTG mice treated for 14 months with CP2 or
vehicle (n= 5 per group), according to the manufacturer’s instructions.
Levels of senescent cells in adipose tissue. The senescent cell burden was
assayed by senescent associated β-galactosidase (SA-β-Gal) staining of freshly
isolated fat biopsies from 23-month-old APP/PS1 and NTG mice, treated for
14 months with CP2, or vehicle (n= 5–6 per group) as previously described79. In
brief, about 100 mg of periovarian and inguinal fat pads were fixed in PBS con-
taining 2.0% formaldehyde and 0.2% glutaraldehyde for 10 min. After fixation,
tissue was washed and incubated with SA-β-gal staining solution for 16–18 h at 37 °
C. The enzymatic reaction was stopped by washing tissue with ice cold PBS. Tissues
were counterstained with DAPI, and ten to twelve random images were taken per
sample with an EVOS microscope under 20x magnification in bright and fluor-
escent fields. SA-β-gal positive senescence cells and total cell number (DAPI+
nuclei) were quantified per field. SA-β-gal positive cell numbers were expressed as a
percent of the total cell number per image. Representative images are included in
the paper. Additional images are available upon request directed to Dr. E.
Trushina.
Metabolomics profiling for ceramide panel in blood. Blood was collected from
fasting (16 h) 23-month-old APP/PS1 and NTG mice treated for 14 months with
CP2 or vehicle (n= 5 per group) by orbital bleeding. Concentrations of ceramides
were established using targeted metabolomics at the Mayo Clinic Metabolomics
Core using their established SOP as described previously80.
Metabolomics profiling in brain. Fasting (12 h) APP/PS1 and NTG mice treated
for 6 months with CP2 or vehicle (n= 5 per group) were sacrificed by cervical
dislocation; brains were rapidly removed; hippocampal tissue was dissected and
immediately flash-frozen in liquid N2. Tissue was pulverized under liquid N2 and
extracted in a solution containing 0.6 M HClO4 and 1 mM EDTA. Extracts were
neutralized with 2M KHCO3 and used for metabolomic analysis as described in
ref. 81. An aliquot of 100 µl of extract was transferred into Eppendorf tube and
spiked with 5 µl IS, myristic-d27 acid (1 mg/ml) at ambient temperature. Samples
were gently vortexed and completely dried in a SpeedVac concentrator. The lyo-
philized brain samples were methoxiaminated and derivatized same way as for
plasma samples. For GC-MS analysis, we used conditions previously optimized for
an Agilent 6890 GC oven with Agilent 5973 MS82. Nucleotides were separated on a
reversed-phase Discovery C18 columns (SIGMA, St. Louis, MO) with Hewlett-
Packard series 1100 HPLC system (Agilent, Santa Clara, CA). The Agilent Fiehn
GC/MS Metabolomics RTL Library was employed for metabolite identification.
GC-MS spectra were deconvoluted using AMDIS software. After that, SpectCon-
nect software was used to create the metabolite peaks matrices.
Electrophysiology. APP/PS1 and NTG mice 15–18 months of age treated for
~10 months with CP2 or vehicle (n= 5 per group) were used for electrophysiology
analysis. Mice were deeply anesthetized with isoflurane and decapitated. Brains
were quickly removed and transferred into a cold slicing solution containing an
artificial cerebrospinal fluid (ACSF), where NaCl was substituted with sucrose to
avoid excitotoxicity. Transverse slices were made at 300–350 µm thickness using a
vibratome (VT-100S, Leica). Slices were incubated in ACSF containing 128 mM
NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 10 mM glucose, 2 mM
CaCl2, and 1 mM MgSO4, aerated with 95% O2/5% CO2. Slices were maintained at
32 °C for 13 min, and then maintained at room temperature throughout the entire
experiment. For electrophysiological recording, each slice (2–3 slices per mouse)
was transferred to a recording chamber, and ACSF was continuously perfused at
the flow rate of 2–3 ml/min. A single recording electrode and a single bipolar
stimulation electrode were placed on top of the slice. A boron-doped glass capillary
(PG10150, World Precision Instruments) was pulled with a horizontal puller (P-
1000, Sutter Instrument) and filled with ACSF for extracellular recording. Under
the microscope (FN-1, Nikon), the recording electrode was placed in the CA1 area
of the hippocampus. The bipolar stimulation electrode (FHC) was placed at the
Schaffer collaterals. The distance between two electrodes was over ~200 µm. To
define a half response of stimulation, various intensities of electrical stimulation
were applied (10–500 µA). However, the pulse width was fixed at 60 µs. Once the
stimulation parameter was determined to generate a half maximum of evoked
fEPSP, this stimulation intensity was used for the paired pulse and LTP experi-
ments. The paired pulse stimulation protocol was applied with 50, 100, and 200 ms
intervals. For the LTP experiment, test stimulation was applied every 30 s for 30
min to achieve a stable baseline. Once the stable baseline was achieved, a tetanic
stimulation (100 Hz for 1 s) was applied three times at a 30-s intervals. Initial slopes
of the fEPSP were used to compare synaptic strength. fEPSP slops were analyzed
using pCLAMP v. 10.5 software.
Mitochondrial DNA (mtDNA) copy number. Genomic DNA was isolated from
snap-frozen cortico-hippocampal brain sections from NTG and APP/PS1 mice
treated with vehicle or CP2 (n= 5 per group) for 14 months using a DNeasy Blood
and Tissue Kit (QIAGEN, cat. # 69504) according to the manufacturer’s instruc-
tions. Quantification of mtDNA copy number was performed in triplicates using
100 ng of isolated DNA. qRT-PCR was performed using a iTaq™ DNA Polymerase
(Bio-rad, cat. # 1708870) and primers for a genomic locus (b-actin) and a mito-
chondrial gene (mND5). Primers for b-actin were the following: forward sequence
(5′-GAT CGA TGC CGG TGC TAA GA-3′); reverse sequence (5′-GGA AAA
GAG CCT CAG GGC AT-3′). Primers for the amplification of mND5: forward
sequence (5′-TGT AAA ACG ACG GCC AGT AGC CCT TTT TGT CAC ATG
AT-3′); reverse sequence (5′-CAG GAA ACA GCT ATG ACC GGC TCC GAG
GCA AAG TAT AG-3′). Thermal cycling protocol was as following: 10 min at
50 °C, 1 min at 95 °C, 10 s at 95 °C, 30 s at 60 °C. Cycles were repeated for 35 times.
The relative mitochondrial DNA copy number was calculated as a ratio of genomic
vs. mitochondrial DNA. Delta Ct (ΔCt) equals the sample Ct of the mitochondrial
gene (mND5) subtracted from the sample Ct of the nuclear reference gene
(B-Actin).
Two-dimensional transmission EM (2D TEM). Hippocampal tissue from APP/
PS1 and NTG mice treated with CP2 or vehicle for 12–14 months (n= 5 per
group) was dissected, cut into 1 mm thick sections, and fixed in 4% paraf-
ormaldehyde +1% glutaraldehyde in 0.1 M phosphate buffer for 24 h. Fixed tissue
was further cut into smaller (1 mm3) pieces and placed into 8 ml glass sample vials
(Wheaton, cat # 225534). Processing was facilitated by the use of a Biowave®
laboratory microwave oven set to 150W (Ted Pella Inc., Redding, CA) and
included the following steps: (1) 0.1 M phosphate buffer (PB), pH 7.0, 40 s on,
2 min rest at RT, repeat three times; (2) 2% osmium tetroxide in H2O, 40 s on, 40 s
off, 40 s on, 15 min rest at RT; (3) H2O rinse, 40 s on, 2 min rest at RT, repeat three
times; (4) 2% aqueous uranyl acetate, 40 s on, 40 s off, 40 s on, 15 min rest at RT;
(5) H2O rinse, 40 s on, 2 min rest at RT, repeat three times; (6) sequential dehy-
dration in ethanol series 60%, 70%, 80%, 95%, 100%, 100% acetone, 100% acetone,
40 s on, 2 min rest at RT each. Resin infiltration steps were performed as follows:
(1) 1:2 resin:acetone, 40 s on, 40 s off, 40 s on, 15 min rest with the vacuum; (2) 1:1
resin:acetone, 40 s on, 40 s off, 40 s on, 15 min rest with the vacuum; (3) 3:1 resin:
acetone, 40 s on, 40 s off, 40 s on, 30 min rest with the vacuum; (4) 100% resin 40 s
on, 40 s off, 40 s on, overnight rest with the vacuum. The next day samples were
moved to fresh resin in embedding molds and incubated at 60 °C for 24 h to
polymerize. Ultrathin sections (silver interference color, ~0.1 µm) were place on
150 mesh copper grids and stained with lead citrate. Images were acquired using a
JEOL 1400+ TEM operating at 80 kV equipped with a Gatan Orius camera. For
conventional 2D TEM, approximately 50 images were taken randomly within each
section for the analysis. All images used for the analysis were taken at ×5000
magnification. For 2D TEM analysis of mitochondrial morphology, organelles were
scored according to their appearance as elongated (>2 μm long) or small (circular
0.5 μm in diameter). Twenty random areas from each CA1 region were imaged,
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and only neuropils longer than 3 μm were selected for the analyses. Representative
images are included in the paper. Additional images are available upon request
directed to Dr. E. Trushina.
Three-dimensional (3D) EM using serial block face scanning electron
microscopy (SBFSEM). Images for 3D EM reconstructions were obtained using an
ApreoVolumeScope (Thermo Fisher Scientific) electron microscope that combines
an integrated serial block face microtome (SBF) and high-resolution field emission
scanning (SEM) imaging. Hippocampal CA1 region was dissected from vehicle and
CP2-treated NTG and APP/PS1 mice, cut into 2 mm3 pieces, and immersion-fixed
in neutral 2.5% glutaraldehyde+ 2.5% paraformaldehyde in 0.1 M cacodylate
buffer+ 2 mM CaCl2. Following 24 h fixation, samples were processed using the
following protocol based on the serial block-face method developed by the National
Center for Microscopy and Imaging Research (La Jolla, CA; https://ncmir.ucsd.
edu/sbem-protocol): (1) samples were rinsed 4 × 3min in 0.1 M cacodylate buffer
+ 2 mM CaCl2, (2) incubated in 2% osmium tetroxide in 0.15M cacodylate buffer
for 1.5 h rotating at RT, (3) incubated in 2% osmium tetroxide+ 2% potassium
ferrocyanide in 0.1 M cacodylate for 1.5 h rotating at RT, (4) rinsed in H2O 4 ×
3min, (5) incubated in 1% thiocarbohydrazide (TCH) 45 min at 50 °C, (6) rinsed
in H2O 4 × 3min, (7) incubated in fresh 2% osmium tetroxide in H2O 1.5 h
rotating at RT, (8) rinsed in H2O 4 × 3 min, (9) incubated in 1% aqueous uranyl
acetate overnight at 4 °C, (10) further incubation in uranyl acetate 1 h at 50 °C, (11)
rinsed in H2O 4 × 3min, (12) incubated in lead aspartate 1 h at 50 °C, (13) rinsed in
H2O 4 × 3min, (14) dehydrated through ethanol series (60, 70, 80, 95, 100, 100%)
10 min each, (15) two rinses in 100% acetone 10 min each, (16) resin 1:2, 1:1, 3:1 in
acetone 0.5 h, 1 h, 2 h, overnight in 100% resin. Samples were embedded into the
Durcapan hard resin (EMS, Hatfield, PA), and allowed to polymerize at a mini-
mum of 24 h prior to trimming and mounting. Tissue was trimmed of all sur-
rounding resin and adhered to 8 mm aluminum pins (Ted Pella Inc., Redding, CA)
using EpoTek silver epoxy (EMS, Hatfield, PA). A square tower (0.5 mm) was
trimmed from the tissue using a Diatome ultratrim knife (EMS, Hatfield, PA) and
the entire pin was coated with gold palladium. Following coating, the block was
trimmed to a planer surface using a diamond knife, and the pin was mounted in
the SEM microtome. Serial block-face images were acquired using a Thermo Fisher
Volumescope (Thermo Fisher, Inc., Waltham, MA) at 50 nm section depths with
detector acceleration voltage of 1.5 kV. Voxel size ranged between 8 and 14 nm
according to magnification. For each region of interest (ROI), 400 sections were
obtained, registered, and filtered using non-local means. All images used for the
analysis were adjusted to ×5000 magnification. Segmentation and three-
dimensional analysis was performed using Reconstruct (SynapseWeb)83 and Amira
6.4 software (Thermo Fisher, Inc., Waltham, MA).
Image segmentation and quantitative morphometric analysis of dendritic
spines using 3D EM. Aligned and normalized stacks of serial sections were further
processed with unsharp masking, Gaussian blur and non-local means filters were
applied in order to clearly distinguish cellular membranes. Dendrites, dendritic
spines and synapses (the PSD and the opposed presynaptic membranes) were
segmented by manually tracing contours in consecutive micrographs. Each seg-
mented dendritic spine or synaptic junction was identified independently. Once the
dendrite reconstruction was completed in Reconstruct, traces were modified by an
absolute intensity and maximal thresholding approach and exported in JPEG
format into Amira software. The magic wand tool in Amira’s segmentation mode
was used to pull out the reconstructions from the Reconstruct exports. Dendritic
spines were cut from their parent dendritic shaft through the base of their neck in a
3D optimal orientation and analyzed using the label analysis function in Amira’s
project view. The label analysis was customized to measure 3D length, surface area,
and volume of the spines. By using the measure tool in Amira’s project view, length,
width of the head and length of the neck of each dendritic spine were established.
The following classifications for dendritic spine type were adapted from40: bran-
ched (2 or more heads); filopodium (length > 2 μm, no bulbous head); mushroom
(length 1 < x > 2 μm; head > 0.6 μm); long thin (length 1 < x < 2 μm; head < 0.6 μm);
thin (length < 1 μm; head < 0.6 μm); and stubby (length < 1 μm; length: width ratio
< 1). In addition to the frequency of individual spine types, their activity (based on
the presence of synaptic vesicles), volume and size (length and width) of spines
were also estimated. To evaluate the impact of nanoscale alterations in spine
morphology on the diffusional coupling between spines and dendrites that promote
long-term potentiation, we calculated the compartmentalization factor, which is
defined as CF=V × L/A where V is the spine head volume, L is the spine neck
length, and A is the cross-sectional area of the spine neck42. Representative images
are included in the paper. Additional images are available upon request directed to
Dr. E. Trushina.
Next-generation RNA sequencing. Brain tissue, encompassing the hippocampal
and cortical regions, from APP/PS1 and NTG mice treated with vehicle of CP2 for
14 months (n= 5 per group) were lysed in QIAzol (Qiagen cat. # 79306) followed
by RNA isolation using miRNeasy (Qiagen cat. # 217004) according to the man-
ufacturer’s instructions. The quantity and quality of RNA were measured using a
NanoDrop spectrophotometer and Agilent 2100 Bioanlyzer, respectively. All RINs
(RNA integrity numbers) had a value greater than eight.
Library preparation and sequencing. Total RNA (200 ng) was used to generate
libraries using TruSeq RNA Library Prep Kit v2 (Illumina). All samples were
sequenced at the Mayo Clinic Medical Genome Facility (MGF) Sequencing Core by
Illumina HiSeq 4000 with paired end 101-bp read length. Approximately 50 mil-
lion single fragment reads were acquired per sample.
Bioinformatics methods. MAP-RSeq v 2.1.1, a comprehensive computational
pipeline developed by the Mayo Clinic’s Division of Biomedical Statistics and
Informatics, was used to analyze RNA-Sequencing data. MAP-RSeq uses a variety
of publicly available bioinformatics tools tailored by methods developed in-house.
The main outputs of the MAP-RSeq workflow are the gene counts, expressed single
nucleotide variants (eSNVs), gene fusion candidates, and quality control plots. The
aligning and mapping of reads was performed using TopHat2 against the mm10
reference genome. The gene and exon counts were generated by FeatureCounts
using the gene definitions files from Ensembl. ‘-O’ option within FeatureCounts
was used to account for expression derived from regions shared by multiple
genomic features. FeatureCounts was also executed for quantifying expression on a
per exon basis by utilizing the ‘-f’ option. RSeqQC84 was used to create a variety of
quality control plots to ensure the results from each sample were reliable and could
be collectively used for differential expression analysis. Upon the completion of all
the deliverables from MAP-RSeq, a html document was created tying everything
together in one interactive document. The R bioinformatics package DeSeq2 was
used for differential gene expression analysis. The criteria for the selection of
significant differentially expressed genes was P value < 0.05. Gene function
enrichment was determined using the Database for Annotation, Visualization and
Integrated Discovery (DAVID v. 6.8)85. Mouse transcriptional factors were
downloaded from the Riken genome database and mapped to our RNA-seq dif-
ferential gene list. The clustering heatmaps were generated based on unsupervised
hierarchical clustering using Pearson correlation distance. Most graphs were gen-
erated using customized R programs. RNA seq data availability: (GEO accession ID
is GSE149248). Code (R script) used to generate final RNA seq analysis is available
in Supplementary Data 22, 23.
Mapping mouse genes to human AD genes from the AMP-AD study. The
differentially expressed genes from our RNA-seq data using mouse model were
identified as described in the differential analysis section. The upregulated and
downregulated genes in comparison of control and AD females were from the
AMP-AD data set. The human data and analysis process were described in Wan
et al.86. The upregulated genes in the RNA-seq data of the mouse NTG vs. AD
comparison were overlapped with the human upregulated gene list. The down-
regulated genes in mouse data were overlapped with the human downregulated list.
Gene function enrichment analysis was performed on the overlapped list of DEGs
using NCBI DAVID function analysis tools with a P value cutoff of less than 0.05.
Similar analyses were performed on the 567 genes overlapped in the two differ-
ential gene lists of NTG vs. AD and AD vs. AD+ CP2 comparisons. All genes are
presented in the Supplementary Data 2–19.
Comprehensive laboratory animal monitoring system (CLAMS). The CLAMS
(Columbus Instruments, Columbus, OH) allows automated, non-invasive, and
simultaneous monitoring of horizontal and vertical activity, feeding and
drinking, oxygen consumption, and CO2 production of an individual mouse.
APP/PS1 and NTG mice treated with vehicle or CP2 (16–18-month-old, n=
15–20 per group) were individually placed in CLAMS cages. Indirect calorimetry
was monitored over 2 days, when mice were allowed food for 24 h ad lib (Fed
state), and for the following 24 h food was removed (Fasting state). Mice were
maintained at 20–22 °C under a 12:12 h light–dark cycle. All mice were accli-
matized to CLAMS cages for 3–6 h before recording. Sample air was passed
through an oxygen sensor for the determination of oxygen content. Oxygen
consumption was determined by measuring oxygen concentration in the air
entering the chamber compared with air leaving the chamber. The sensor was
calibrated against a standard gas mix containing defined quantities of oxygen,
carbon dioxide, and nitrogen. Food and water consumption were measured
directly. The hourly file displayed measurements for the following parameters:
VO2 (volume of oxygen consumed, ml/kg/h), VCO2 (volume of carbon dioxide
produced, ml/kg/h), RER (respiratory exchange ratio), heat (kcal/h), total energy
expenditure (TEE, kcal/h/kg of lean mass), activity energy expenditure (AEE,
kcal/h/kg of lean mass), resting total consumed food (REE kcal/h/kg of lean
mass), food intake (g/kg of body weight/12 h), metabolic rate (kcal/h/kg), total
activity (all horizontal beam breaks in counts), ambulatory activity (minimum 3
different, consecutive horizontal beam breaks in counts), and rearing activity (all
vertical beam breaks in counts). The RER and atty acid (FA) oxidation were
calculated using the following equations: RER= VCO2/VO2; FA oxidation
(kcal/h)= TEE × (1− RER/0.3). Daily FA oxidation was calculated from the
average of 12 h of hourly FA oxidation. Daily carbohydrate plus protein oxi-
dation was calculated from average of 12 h of hourly TEE minus daily FA oxi-
dation. Metabolic flexibility was evaluated from the difference in RER between
daily fed state and fasted state recorded at night phase, according to the fol-
lowing equations: Δ= 100% × (RER fed–RER fasted)/RER fed.
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Dual energy X-ray absorptiometry (DEXA). A LUNAR PIXImus mouse den-
sitometer (GE Lunar, Madison, WI), a dual-energy supply X-ray machine, was used
for measuring skeletal and soft tissue mass for the assessment of skeletal and body
composition in CP2 or vehicle-treated mice. Live mice were scanned under 1.5–2%
isoflurane anesthesia. Mice were individually placed on plastic trays, which were
then placed onto the exposure platform of the PIXImus machine to measure body
composition. The following parameters were generated: lean mass (g), fat mass (g),
and the percentage of fat mass. These parameters were used to normalize data
generated in CLAMS, including O2, VCO2, metabolic rate and energy expenditure.
In vivo 31P NMR spectroscopy. NMR spectra were obtained in 16–18-month-old
APP/PS1 and NTG mice treated with CP2 or vehicle for 8 months (n= 5 per
group) using an AVANCE III 300MHz (7 T) wide bore NMR spectrometer
equipped with micro-imaging accessories (Bruker BioSpin, Billerica, MA) with a
25-mm inner diameter dual nucleus (31P/1H) birdcage coil. For anatomical posi-
tioning, a pilot image set of coronal, sagittal, and axial imaging planes were used.
For 31P NMR spectroscopy studies, a single pulse acquisition with pulse width: P1
200 us (~30°), spectral width: SW 160 ppm, FID size: TD 16 k, FID duration: AQT
0.41 s, waiting time: D1 1 s and number of scans: NS 512 was used. The acquisition
time was 12 min. Spectra were processed using TopSpin v1.5 software (Bru-
kerBiospin MRI, Billerica, MA). Integral areas of spectral peaks, corresponding to
inorganic phosphate (Pi), phosphocreatine (PCr), and γ, α, and β phosphates of
adenosine triphosphate (αATP, βATP, and γATP), were analyzed using jMRUI
software. Since in some mice, the Pi peaks were not detectable, Pi values were
uniformly omitted from the analyses. The presence of phosphomonoester (PME)
or phosphodiester (PDE) peaks was also recorded. However, the signal-to-noise
ratio of these peaks was not always adequate for accurate quantification. Levels of
PCr and Pi were normalized to the total ATP levels present in that spectrum or to
the amount of βATP. Results were consistent between both of these normalization
methods; data are presented as the ratio of each parameter to total ATP.
Western blot analysis. Levels of proteins were determined from the cortico-
hippocampal region of the brain of vehicle and CP2-treated NTG and APP/PS1
mice (n= 6–8 mice per group) by Western blot analysis. Tissue was homogenized
and lysed using 1× RIPA Buffer plus inhibitors. Total protein lysates (25 µg) were
separated in equal volume on 4–20% Mini-PROTEAN TGX™ Precast Protein Gels
(Bio-Rad, cat. # 4561096) and transferred to an Immun-Blot polyvinylidene
difluoride membrane (PVDF cat. # 1620177). The following primary antibodies
were used: phospho-AMPK (Thr 172) (1:1000, Cell Signaling Technology, cat. #
2535), AMPK (1:1000, Cell Signaling Technology, cat. # 2532), phospho-Acetyl-
CoA Carboxylase (Ser79) (1:1000, Cell Signaling Technology, cat. # 11818),
Synaptophysin (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, cat. # 17750),
BDNF (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, cat. # 546), PSD95
(1:1000, Cell Signaling Technology, cat. # 2507), Sirt3 (1:1000, Cell Signaling
Technology, cat. # 5490), IGF1 (1:2000, Abcam, cat. # ab223567), Superoxide
Dismutase 1 (1:1000, Abcam, cat. # ab16831), phospho-IGF-I Receptor β
(Tyr1131)/Insulin Receptor β (Tyr1146) (1:1000, Cell Signaling Technology, cat. #
3021), IGF-I Receptor β (1:1000, Cell Signaling Technology, cat. # 3027), phospho-
Pyruvate Dehydrogenase α1 (Ser293) (1:1000, Cell Signaling Technology, cat. #
31866), Pyruvate Dehydrogenase (1:1000, Cell Signaling Technology, cat. # 3205),
Glut4 (1:1000, Cell Signaling Technology, cat. # 2213), Glut3 (1:1000, Santa Cruz
Biotechnology, cat. # sc-74399), phospho-ULK1 (Ser555) (1:1000, Cell Signaling
Technology, cat. # 5869), phospho-ULK1 (Ser317) (1:1000, Cell Signaling Tech-
nology, cat. # 12753), phospho-Beclin-1 (Ser15) (1:1000, Cell Signaling Technol-
ogy, cat. # 84966), PGC1α (1∶1000, Calbiochem, cat. # KP9803), TFAM (1:1000,
Sigma-Aldrich, cat. # AV36993), phospho-NF-κB p65 (Ser536) (1:1000, Cell Sig-
naling Technology, cat. # 3033), HO-1 (1:1000, Cell Signaling Technology, cat. #
70081), IκBα (1:1000, Cell Signaling Technology, cat. # 4812), Nrf2 (1:1000,
Abcam, cat. # ab62352), LC3B (1:1000, Novus Biologicals, cat. # NB100-2220),
TFEB (1:500, Thermo Fisher, cat. # PA5-75572), LAMP1 (1:1000, Cell Signaling
Technology cat. # 9091), Catalase (1:1000, Cell Signaling Technology cat. # 14097),
Tubulin (1:5000, Biovision, cat. # 3708), β-Actin (1:5000, Sigma-Aldrich, cat. #
A5316). The following secondary antibodies were used: donkey anti-rabbit IgG
conjugated with Horseradish Peroxidase (1:10,000 dilution, GE Healthcare UK
Limited, UK) and sheep anti-mouse IgG conjugated with Horseradish Peroxidase
(1:10,000 dilution, GE Healthcare UK Limited, UK). Ban quantification was done
using Image LabTM v. 6.0.
Statistics and reproducibility. The statistical analyses were performed using the
GraphPad Prism (Version 8, GraphPad Software, Inc., La Jolla, Ca). Statistical
comparisons among four groups concerning behavioral and metabolic tests,
immunoreactivity, metabolomics, plasma cytokine panel, body composition, elec-
tron microscopy imaging, FDG-PET, 31P NMR, electrophysiology, were analyzed
by two-way ANOVA, the two-tailed unpaired and paired Student t test, where
appropriate. The Fisher’s LSD post hoc analysis was used if significant interaction
among groups was found. A linear regression analysis was applied to determine
differences among the groups in body weights and age-related loss of TH+ axons
and neurons. Significant differences between vehicle and CP2-treated groups
within the same genotype and differences among NTG, APP/PS1, and APP/PS1+
CP2 mice were considered in the final analysis. Data are presented as mean ± S.E.
M. for each group of mice. All P values generated in this study are presented in
Supplementary Data 20, and individual values used to generate plots in the
manuscript are presented in Supplementary Data 21. Sample sizes were determined
by setting a minimum n number for in vitro biological replicates at 3, to allow for
statistical testing, however in most cases n numbers were higher. All replicates
displayed in this paper are biological replicates, technical replicates (usually 3) were
performed and used to generate the means for each biological replicate. At the
initiation of each experiment, all available data from previous studies were assessed
and used to adequately design the experiment to have at least 80% power to detect
a biologically meaningful effect size while controlling the type I error rate at 5%.
Animal allocation to treatment groups was randomized. We were blinded to both
the genetic and treatment information, being unblinded after analysis was
complete.
Data availability
RNA-seq data generated in this study using mice that support the findings are deposited
to public repository and are freely available at: (GEO accession ID is GSE149248). Source
data underlying plots shown in figures are presented in Supplementary Data 21. Full
blots are available in Supplementary Information.
Code availability
Code (R script) used to generate final RNA seq data analysis is available in
Supplementary Data 22 and 23.
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